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ABSTRACT
Uniform microspheres (MS) of biocompatible polymers were investigated 
for use as advanced drug delivery vehicles. Novel methods of fabricating the 
precision particles (i.e., precision particle fabrication (PPF) techniques) of 
biomaterials were developed utilizing mechanical, hydrodynamic and electric 
forces. A number of biodegradable/biocompatible polymers, such as ethyl cellulose 
(EC), chitosan, starch, and gelatin, were employed to investigate their 
characteristics and suitability as drug carriers. Because the MS size determines the 
drug diffusion and/or the degree of polymer degradation, the drug release kinetics 
could be accurately controlled without uncertainties resulting from uncontrolled 
size distribution.
Monodisperse MS of EC with two different polymer viscosities (4- and 45- 
cp) were fabricated by the PPF method. With use of a surfactant, uniformly 
generated EC solution drops could be successfully separated until dry EC MS were 
obtained by solvent evaporation at room temperature. The drugs encapsulated in 
the EC MS tended to concentrate near the surface depending on their hydrophilicity. 
The more hydrophilic the drug, the more concentration near the surface. The 30- 
and 35-pm MS exhibited more even distribution of the drug than the larger ones, 
possibly due to their fast hardening. The 30- and 35-pm MS of 4 cp EC showed 
almost linear release during the first 24 hrs for both hydrophilic and hydrophobic 
drugs.
To fabricate uniform MS of a hydrophilic polymer (hydrogel) such as 
chitosan, starch, and gelatin, an electric force was utilized to separate the uniformly 
generated drops. Both direct and indirect drop charging were incorporated, 
resulting in coulombic repulsion among the drops. Because no surfactant was 
involved, the method became nontoxic. For chitosan and starch, the dry MS were
iii
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obtained by solvent evaporation at a high temperature (140 ~ 160 °C). However, 
due to their degradation at such high temperature, the gelatin solution drops were 
gelled at a low temperature ( 0 - 4  °C). The solvent was extracted afterwards 
utilizing acetone. Uniform hydrogel MS with three different sizes were 
successfully fabricated regardless of the kinds of hydrogels used.
Gelatin MS (GMS), 60-pm in diameter, were crosslinked using 
glutaraldehyde solutions with different concentrations. An acidic drug was 
introduced to form polyion complex with GMS, thereby prolonging the drug 
release. More sustained drug release was obtained with higher glutaraldehyde 
concentrations. As a result of glutaraldehyde concentration gradient in the MS, 
heterogeneous crosslinking seemed to exist. The amount of complexed drug near 
the surface decreased as the glutaraldehyde concentration increased. In situ study 
of the degradation profiles of the GMS with higher glutaraldehyde concentrations 
revealed faster erosion at the center than near the surface.
Uniform chitosan MS (CMS) were employed for precisely controlled 
delivery of acidic drug, where colon-specific delivery could be realized without 
any additive polymers or toxic process. For strong acidic drug with multiple 
anionic functional groups, the smaller the CMS, the more drugs could be contained 
until the colonic site hence the better candidate for colon-specific delivery. Weak 
acidic drug preferred the larger CMS due to the smaller amount of release at the 
gastric fluid.
iv
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
A C K N O W L E D G M E N T S
Thanks be to God for His love and blessing beyond description throughout 
my whole life.
I wish to thank my adviser, Professor Kyekyoon Kim, for his continuous 
support, encouragement, and help in this research, and Professor Hyungsoo Choi, 
for her guidance and special advice on chemistry throughout this work. Their 
support and love like good parents set an excellent example for me. I would also 
like to thank my PhD committee members, Professors Russell Jamison, Bruce 
Wheeler, and Brian Cunningham, for their guidance and help. I am also grateful to 
Dr. Cory Berkland, who patiently taught me the recipes for material preparation 
and in-vitro drug release study.
I would like to thank all members of the Thin Film and Charged Particle 
Research Laboratory for their help and support. Their kindness and friendship will 
never be forgotten. I am particularly thankful to Hee Kyung and Felice Cheng for 
their assistance with the particle fabrication and characterization. I will not forget 
the brotherhood with Seung Jae Hong, Changwook Kim, Huichan Seo, Sangho 
Lim, and Jinkeun Park. The discussion with Ravindra Singh, Anil Kumar, and Phil 
Heil will also be in my pleasant memory.
I am thankful to Professor Russell Jamison and his group members for 
their useful suggestions. Many thanks go to Abby Morgan and Aylin Sendemir- 
Urkmez for their masterful work on tissue engineering with our gelatin 
microspheres. I would like to thank Professor Jamison for providing us the gelatin 
and allowing us to use the optical microscope. Thanks also go to Professor Daniel 
Pack for allowing us to use the spectrophotometer in his lab and to Summer 
Rhodes and Professor Jennifer Lewis for helping me with the measurement of zeta- 
potential.
v
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
I would like to thank Pastor Rick Bloom and his wife, Denise Bloom, for 
their continuous prayer for the life of our family in Christ. I thank my wife, Young 
Mi Kim, son, Tobias Tae-Hwan Choy, and all other family members for their love 
and help. Thanks also go to my parents-in-law for their continuous support. I wish 
to thank my mother for guiding me with her unconditional love. I especially thank 
my father, Professor Jin-Ho Choy, for introducing me to science and engineering 
and for continuously maintaining interest in my work.
This work was financially supported by the University o f Illinois.
vi
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
T A B L E  O F  C O N T E N T S
CHAPTER 1 INTRODUCTION...................................................................................1
CHAPTER 2 PRECISION PARTICLE FABRICATION METHOD FOR
BIOCOMPATIBLE POLYMERS.......................................................5
2.1 Generation of Uniform Polymer Solution Drops................ 5
2.2 Prevention of Drop Agglomeration....................................... 6
2.3 Particle Hardening................................................................... 8
2.4 Apparatus for Precision Particle Fabrication.................... 9
2.5 Figures.....................................................................................10
CHAPTER 3 UNIFORM ETHYL CELLULOSE MICROSPHERES OF
CONTROLLED SIZES AND POLYMER VISCOSITIES AND 
THEIR DRUG RELEASE PROFILES............................................ 15
3.1 Purpose....................................................................................15
3.2 Materials and Experimental Methods.................................17
3.2.1 Materials................................................................... 17
3.2.2 Microsphere preparation.........................................17
3.2.3 Particle size distribution.........................................17
3.2.4 Scanning electron microscopy (SEM).................. 18
3.2.5 Confocal microscopy.............................................. 18
3.2.6 In vitro drug release................................................ 18
3.3 Results..................................................................................... 19
3.3.1 Preparation of drug-loaded microspheres.............19
3.3.2 Drug distribution in the microspheres..................20
3.3.4 In vitro drug release study..................................... 21
3.4 Discussion.............................................................................. 22
3.5 Conclusion........................................................ 24
3.6 Figures and Table.................................................................. 25
CHAPTER 4 A NOVEL ELECTRIC FIELD ASSISTED METHOD
FOR FABRICATION OF UNIFORM BIODEGRADABLE 
HYDROGEL MICROSPHERES......................................................30
4.1 Hydrogel Microspheres for Controlled Drug Release... .30
4.2 Conventional Fabrication Methods and
Their Problems......................................................................32
4.3 Fabrication and Characterization of Uniform Hydrogel
Microspheres......................................................................... 33
4.3.1 Materials.................................................................. 34
4.3.2 Preparation of uniform hydrogel microspheres..34
4.3.3 Characterization......................................................36
4.4 Results and discussions........................................................ 36
4.5 Conclusion.............................................................................37
4.6 Figures.................................................................................... 38
vii
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
CHAPTER 5 DRUG RELEASE PROFILES OF UNIFORM GELATIN
MICROSPHERES UNDER DIFFERENT CROSS-LINKING 
CONDITIONS.....................................................................................42
5.1 Crosslinked Gelatin Microspheres......................................42
5.2 Experimental..........................................................................43
5.2.1 Cross-linking uniform gelatin microspheres...43
5.2.2 Drug loading.......................................................... 44
5.2.3 In vitro drug release study................................... 44
5.2.4 Observation of intraparticle drug distribution..44
5.2.5 Zeta-potential measurement................................ 45
5.2.6 In situ degradation study.........................................45
5.3 Results and Discussion......................................................... 45
5.4 Conclusion.............................................................................50
5.5 Figures and Table.................................................................. 52
CHAPTER 6 UNIFORM CHITOSAN MICROSPHERES WITH
DIFFERENT CROSSLINKING DENSITIES FOR ORAL 
DELIVERY..........................................................................................58
6.1 Chitosan Microspheres for Oral Delivery........................... 58
6.2 Purpose....................................................................................59
6.3 Materials and Experimental Methods.................................61
6.3.1 Materials................................................................... 61
6.3.2 Preparation of uniform chitosan microspheres...61
6.3.3 Drug loading in chitosan microspheres 62
6.3.4 Characterization..................................................... 62
6.3.5 Drug distribution in the microspheres..................62
6.3.6 In vitro drug release............................................. 63
6.4 Results.....................................................................................63
6.4.1 Differently crosslinked uniform chitosan
microspheres......................................................................... 63
6.4.2 Drug distribution....................................................64
6.4.3 In vitro drug release study......................................65
6.5 D iscussion............................................................................. 67
6.6 Conclusion............................................................................. 69
6.7 Figures and Tables................................................................. 70
CHAPTER 7 CONCLUSIONS.................................................................................. 86
REFERENCES................................................................................... 90
AUTHOR’S BIOGRAPHY............................................................ 103
viii
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
CHAPTER 1 
INTRODUCTION
With rapid advances in biotechnology, a variety of potent and specific 
drugs were discovered, many of which have become available in the market place 
or under regulatory review by the United States Food and Drug Administration [1, 
2], However, when the bolus drug is administered, due to its high potency and/or 
short half-life, frequent dosing is often needed to maintain therapeutic 
concentrations in a patient’s body. To minimize such inconvenience and improve 
the patients’ comfort and compliance, new devices employing biocompatible 
polymers as delivery vehicles have been widely investigated [3]. The drug 
encapsulated in a polymer could be protected from the severe body milieu and 
released in sustained and controlled manners minimizing unwanted side effects.
Microsphere (MS) of biocompatible polymers is one of the most common 
forms of drug delivery vehicle due to its ease of fabrication, simplicity of 
administration to various sites, and possible use in localized and targeted delivery 
[4], Various polymers were utilized in those purposes. Poly (D,L-lactide-co- 
glycolide) (PLG) has been one of the good candidates of biocompatible and 
biodegradable polymers, widely used to formulate drug-loaded MS. The drugs, 
such as protein, vaccine, and antimicrobial agent, were encapsulated in PLG MS 
and exhibited sustained release for days or months by diffusion and PLG 
degradation [5-7], Ethyl cellulose (EC) has been also widely investigated as a 
material for controlled drug release for various administration routes [8-12], For 
example, indomethacin-loaded EC was studied as a rectal delivery vehicle and 
provided more than 5 h of prolonged release [9, 12], EC MS loaded with potassium 
chloride, aspirin, fenoterol HBr, etc. were studied as oral delivery vehicles 
achieving 24 h of continuous release [8, 10, 13].
1
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In addition to such synthetic polymers, natural hydrogels are known to be 
attractive polymers for encapsulation because of their excellent compatibility with 
tissue, ease of manipulation of their swelling level, and good control on their solute 
permeability [14]. For these reasons, the MS of such hydrogels as chitosan, starch, 
and gelatin have been widely investigated. Due to the cationic charge of chitosan, 
chitosan microspheres (CMS) are considered effective for the delivery of proteins 
and, especially, DNA [15, 16]. Positively charged CMS can form a polyion 
complex with a negatively charged protein/DNA thus prolonging their release [17, 
18]. CMS were also used for site-specific delivery: due to their bioadhesiveness, 
the residence time of CMS in the lung and stomach increased, facilitating targeted 
drug delivery [19, 20]. Starch, another natural hydrogel, has been explored as a 
material for drug delivery because it is cheap, inert, biocompatible, and 
biodegradable [21]. MS of various starches were studied as adjuvant in oral 
immunization and as a protein delivery system [22, 23], Gelatin microspheres 
(GMS) have been of great interest because of their excellent biocompatibility and 
degradation to non-toxic products [24], Due to their good bioadhesive properties, 
GMS were suggested as a drug carrier for such administration routes as nasal, 
gastrointestinal, and rectal [25, 26]. GMS are well known as good protein delivery 
vehicles since they can be positively or negatively charged to form a polyion 
complex with an oppositely charged protein, prolonging the protein release [27, 28]. 
Due to these favorable properties, GMS have been widely used as a delivery 
vehicle for growth factors in tissue engineering [29, 30],
Drug release from MS-based delivery systems critically depends on the 
size and size distribution of the MS. The critical determinants in drug release, such 
as the rate of diffusion of the drug and degradation of the polymer matrix, were 
strongly influenced by the surface area-to-volume ratio of the particles. For site- 
specific delivery, the MS size was also known to be a critical factor. The MS less
2
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than 10 pm were reported to be effective for the particle transportation via Peyer’s 
patches [31]. The MS, 10-20 pm in diameter, have been used to specifically target 
the tortuous capillary bed of tumor tissues by chemo-embolization [32]. The MS 
size could also determine the porosity of a scaffold. When embedded in a scaffold, 
the MS were shown to function as both digestive porogen and drug delivery vehicle 
[30], To fabricate the MS of biocompatible polymers, various methods such as 
coacervation [33, 34], aqueous precipitation [35, 36], classic emulsion [24, 30, 37, 
38], and spray drying [39-42], were employed. However, due to a lack of control 
over agitation and an inability to prevent drop agglomeration, none of them 
produced uniform MS. In this study, we utilize the precision particle fabrication 
(PPF) method and fabricate uniform MS of various biocompatible polymers with 
precisely controlled size and size distribution. Concurrent use of mechanical and 
hydrodynamic forces allowed the method to be not so limited by the solution 
viscosity or the nozzle dimension, which provided flexibility in particle size control. 
With the use of electric force, originally introduced in this work, particle 
agglomeration was prevented without recourse to toxic surfactants, making the 
method suitable for biomedical application. Most of all, due to the excellent 
uniformity of the resulting MS, the detailed drug release study could be performed 
without uncertainties caused by wide particle size distribution.
In Chapter 2, we explain the theory and background of the PPF scheme to 
understand its significance and advantages. Chapter 3 describes uniform EC MS 
fabricated by the PPF method and the drug release profiles of the drug-containing 
MS. Chapter 4 outlines new improving features of the PPF apparatus that are 
particularly suited to fabrication of uniform hydrogel MS. In Chapters 5 and 6, we 
examine the drug release from thus-prepared uniform hydrogel MS. Chapter 5 
describes the effect of crosslinking on uniform GMS and their drug release profiles. 
In Chapter 6, we investigate uniform CMS with different crosslinking densities for
3
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oral delivery of the drugs with different ionic charges. Chapter 7 summarizes the 
present work and presents concluding remarks.
4
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CHAPTER 2
PRECISION PARTICLE FABRICATION (PPF) METHOD FOR 
BIOCOMPATIBLE POLYMERS
The PPF scheme was evolved from the previous work by Kim and 
colleagues [43-49], in which precision microspheres (MS) and microcapsules 
comprising frozen hydrogen, silica aerogel, and other materials were fabricated. By 
combining mechanical, hydrodynamic, and electric forces, uniform particles with 
micro- or nanosizes were successfully fabricated relatively free from limitations 
imposed by the viscosity of the source solution, dimension o f the drop-producing 
nozzle, and drop agglomeration.
In this chapter, we describe the PPF methodology specifically responsible 
for manufacturing uniform MS of biocompatible polymers and the apparatus built 
to practice the method. The PPF consists of three techniques: generation of uniform 
solution drops, prevention of agglomeration, and particle hardening.
2.1 Generation of Uniform Solution Drops
To fabricate uniform MS, one needs to first generate uniform polymer- 
solution drops. To achieve this, the polymer solution was pumped through a small 
nozzle forming a jet, which was subsequently broken into uniform droplets by 
precisely controlled mechanical (acoustic) force as shown in Figure 2.1(A). All 
figures and tables appear at the end of each chapter. The drop radius predicted by 
Lord Rayleigh [50, 51] is:
rd ~ @r/ vj / 4 / ) 1/3 (2.1)
where rj is the radius of the undisturbed jet, y, the linear velocity of the jet, and/ the
5
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frequency of the acoustic excitation. Thus, the size o f the droplets produced by this 
method, can be accurately controlled by adjusting the jet velocity and the acoustic 
frequency.
However, with this scheme alone, the smallest drop size achievable is 
about twice the nozzle opening. To further reduce the drop size, therefore, the 
nozzle opening has to be accordingly further reduced, which is not applicable to 
high-viscosity solutions. To overcome this difficulty, a hydrodynamic force 
employing a carrier stream was utilized achieving further reduction in the jet 
thickness. As shown in Figure 2.1(B), the carrier stream, consisting of a solvent 
immiscible with an aqueous hydrogel solution, surrounded the jet and was adjusted 
to move faster than the jet. Consequently, the resulting frictional force accelerated 
the jet and made it thinner. This jet was then broken up into uniform drops much 
smaller than the nozzle opening.
Previously, we fabricated uniform MS of various polymers including PLG, 
polyanhydride, etc. [2, 52-54], Because the polymer solutions in this work were an 
oil-phase, water was utilized as a nonsolvent carrier stream. In contrast, when the 
hydrophilic polymer such as hydrogel is employed, the carrier stream needs to be 
an oil phase.
2.2 Prevention of Agglomeration
To minimize the surface energy, smaller drops tend to agglomerate to form 
larger ones. Because of this tendency, the drops, once generated, need to be 
separated to retain their uniform original size. One way to achieve this separation is 
to use a surfactant and reduce the surface tension force of the drops. In our 
previous work, the drops of oil-soluble polymers were seen not to agglomerate 
when a surfactant, polyvinyl alcohol (PVA) was incorporated [2, 52-54]. However, 
with hydrophilic polymers, various attempts using surfactants failed to prevent the
6
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drops suspended in oil phase from coalescing [55, 56].
To resolve this difficulty, an electric field was employed to charge the 
drops with the same polarity. As is well known, the repulsive force between the two 
point charges with the same polarity and amount of charge is [57]:
F  -  Q 2 / 4 ttsR 2 (2.2)
where F  is the force, Q the amount of charge, e the permittivity of the media, and R 
the distance between two points. We utilized both direct and indirect charging 
methods to prevent the drop coalescence. For direct charging, hydrogel solution 
was connected to a high voltage (Figure 2.2(A)) injecting the charge directly 
through induction. However, it might not be safe for a large-scale system because 
the whole apparatus in contact with the hydrogel solution could also experience 
high electric potential if not heavily insulated. To avoid such a problem, an indirect 
charging method (Figure 2.2(B)) was suggested. A conductive ring at a high 
electric potential was placed on the path of a hydrogel solution jet without contact. 
An electric field formed between the ring and the electrically grounded hydrogel 
solution induced the charge into the drops. By this method, only the ring has a high 
electric potential, thereby resolving the possible safety issue caused by direct 
charging
To successfully spread the drops using an electric force, the selection of the 
collection media is critical. While the drops were separated in the media, discharge 
needed to take place very slowly allowing for the drops to harden without losing 
their uniformity. For fabrication o f oil-soluble polymer MS, the method was not 
applicable. The solution drops were suspended in aqueous media, which were 
highly conductive, rapidly losing their charge before being hardened. In contrast, 
the solution drops of hydrophilic polymers such as hydrogel were collected in non-
7
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conducting oil allowing the drops to maintain their charges.
2.3 Particle Hardening
While separated in the collection media, the drops were subjected to 
hardening to convert them into dried MS. The phase of the collection media was 
selected to be immiscible with the polymer solution so that it helped to achieve 
smooth spherical shape of the MS due to the high surface tension force. In contrast, 
air-dried MS were often reported to exhibit nonuniform and rough morphologies 
due to the low interfacial tension between the air and the polymer solution [39, 40].
In this study, we employed three different hardening methods depending 
on the solvent characteristics and the polymer kinds (Figure 2.3). The solvent with 
high vapor pressure was evaporated at room temperature without any other 
treatment while the drops were suspended in the collection media (Figure 2.3(A)). 
In our previous study, the solvent with high vapor pressure, such as methylene 
chloride (350 mmHg at 20 °C), was evaporated at room temperature to obtain dry 
PLG and/or polyanhydride MS [2, 52-54]. However, for the solvent with low vapor 
pressure such as water (17.54 mmHg at 20 °C), the solvent evaporation was 
facilitated by the collection bath heated above their boiling point (140 ~ 160 °C), as 
shown in Figure 2.3(B). This evaporation method, however, was inapplicable to a 
polymer such as gelatin because o f its degradation at high temperatures. Instead, as 
shown in Figure 2.3(C), a low temperature ( 0 - 4  °C) was used for the collection 
bath to cause gellation of the solution drops. These gelled drops were rigid enough 
not to recombine even after charge disappeared. The resulting suspension was 
mixed with acetone afterwards to extract the solvent (water) and obtain the dried 
MS as previously reported [27],
8
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2.4 Apparatus for Precision Particle Fabrication
The apparatus was designed so as to be specially suited to fabrication of 
uniform biocompatible polymer MS as shown in Figure 2.4. A dual nozzle was 
utilized to generate the solution jet thinner than the nozzle orifice, with help o f the 
carrier stream. A typical size of the nozzle opening utilized in this study was about 
250 pm. The nozzle was attached to an ultrasonic wave launcher to introduce a 
mechanical force (acoustic excitation) into the source jet. The energy and 
frequency of the acoustic wave were managed by the electric power supply. The 
drop generation was monitored on a TV screen via a camera and an optical 
microscope. To measure the size of the drops during generation, the still image was 
obtained by using a stroboscope by synchronizing it with the acoustic wave. The 
resulting drops were collected in the nonsolvent media, which were stirred slowly 
to expedite the solvent evaporation or the drop gellation. All the parameters, such 
as the flow rates of the polymer solution and the carrier stream, the acoustic energy, 
and the frequency, were precisely controlled using a computer interface to improve 
accuracy and reproducibility. Figure 2.5 shows the control panel of the PPF 
apparatus, where all the critical parameters could be controlled remotely.
9
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2.5 Figures
Acoustic excitation
Polymer
Solution
Carrier stream
(A) (B)
Figure 2.1 Generation of uniform solution drops (A) from a single 
nozzle, and (B) a dual nozzle employing a carrier stream.
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High
Voltage
Source
Spreading
drops
Voltage
Source
Spreading
drops
nr
Figure 2.2 Drop separation by an electric force. Two different charging 
methods were employed: (A) direct charging, and (B) indirect charging.
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Stirring at 
room temperature
Stirring at 
an elevated temperature
Stirring at 
low temperature
Cooling bath
Figure 2.3 Schematic illustrations of different hardening methods: (A) 
solvent evaporation at room temperature, (B) solvent evaporation at an 
elevated temperature, and (C) gellation of the polymer solution drops at 
low temperature.
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Computer
Computer Interface
71
Polymer
Acoustic Solution
Monitor Excitatio
t
Carrier stream
Stroboscope
Camera Optical
Lens Collection
Bath
Figure 2.4 Simplified schematic of the PPF apparatus for fabrication of 
uniform MS of biocompatible polymers. All the parameters were controlled by 
a computer to improve the reproducibility.
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Figure 2.5 Control panel of computer-based PPF apparatus.
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CHAPTER 3
UNIFORM ETHYL CELLULOSE MICROSPHERES OF
CONTROLLED SIZES AND POLYMER VISCOSITIES AND 
THEIR DRUG RELEASE PROFILES
Monodisperse EC MS were fabricated by the PPF methodology described 
in Chapter 2, which combines mechanical and hydrodynamic forces. Due to the 
excellent uniformity and sphericity of the particles, the drug release profiles 
obtained with the resulting EC MS were free from the uncertainties caused by the 
uncontrolled particle size and morphology. The effect of polymer viscosity was 
examined by employing EC with two distinct viscosities (4- and 45-cp). Piroxicam 
and rhodamine B were used as the model drugs. The drug distribution in the MS 
was examined to see the effect on drug release.
3.1 Purpose
EC, a water-insoluble and pH-independent polymer, has been widely used 
as a material for controlled drug release for various administration routes [8-12, 58, 
59], Several methods of fabricating drug-loaded EC MS, including coacervation 
[11, 33, 34, 60], spray drying [41, 42], and emulsion techniques [13, 37, 38, 60-64], 
have been investigated and the factors affecting the drug release profiles studied. 
The nonsolvents used [37, 60, 61], the amount o f emulsion stabilizer [63], the rate 
of agitation [12, 63, 65], and the molecular weight o f EC [38, 41] were varied to 
examine their respective effects on drug release. However, none of these release 
studies was carried out without the uncertainty stemming from the inability to 
precisely control the size and size distribution of the MS.
It is well known that the shape, size, and size distribution o f drug-loaded 
MS are critical determinants of drug release profiles because the surface area-to-
15
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volume ratio of the MS strongly affects the rate of drug release and/or polymer 
degradation. For example, MS with distorted spherical shape should show different 
drug release from those with smooth spherical shape, even with the same volume 
due to difference in the surface areas. EC MS obtained from coacervation and spray 
drying exhibited irregular shapes with wide size distributions [34, 41]. Most of the 
MS obtained from the emulsion method exhibited smooth spherical shapes [13, 37, 
38, 60-64] but still wide size distributions. The reported standard deviations of the 
size distributions were 20-50% of the average diameters.
We recently fabricated monodisperse MS of poly(D,L-lactide-co- 
glycolide) (PLG) and a few other polymers for use as drug delivery systems using 
the PPF technique [2, 52-54], Following the basic PPF scheme, drug-loaded EC 
MS with uniform size and precisely controlled size distribution were fabricated in 
this work. Piroxicam, a nonsteroidal anti-inflammatory drug (NSAID), and 
rhodamine B were encapsulated as model drugs. Although the two drugs are similar 
in molecular weight, piroxicam was chosen as a representative for water-insoluble 
drugs (53.3 pg/ml at pH -7 ) and rhodamine for water-soluble drugs (7.8 mg/ml) 
[53]. By fabricating monodisperse EC MS with different sizes from two distinct 
viscosities of EC, we were able to investigate the effects of particle size and 
polymer viscosity on the drug release, without the uncertainties associated with the 
particle size variation. EC stocks with viscosities of 4 cp and 45 cp were used. The 
effects of particle surface morphology and drug distribution on drug release were 
studied. The in vitro drug release studies were performed over 24 h mainly to 
investigate the effectiveness of the EC MS as oral/rectal delivery vehicles.
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3.2 Materials and Experimental Methods
3.2.1 Materials
EC with two different viscosities (48% ethoxy, 4 cp; and 49.3% ethoxy, 45 
cp) were obtained from Aldrich. PVA (88% hydrolyzed) was purchased from 
Polysciences. Rhodamine B chloride was acquired from Sigma. Piroxicam freebase 
was a gift from Dongwha Pharmaceuticals (Korea). HPLC-grade dichloromethane 
(DCM) was purchased from Fisher Scientific.
3.2.2 Microsphere preparation
Uniform EC MS with drug loading were fabricated as described in Chapter 
2 (Figures 2.1, 2.3(A), and 2.4). Briefly, to fabricate the drug-loaded EC MS, EC 
was dissolved in methylene chloride (5% w/v) followed by an initial loading of the 
drugs (piroxicam: 5% w/w and rhodamine: 10% w/w). The resulting EC solution 
was fed into a nozzle structure with a syringe pump to produce a smooth liquid jet 
exiting the nozzle opening. A carrier stream (1% w/v PVA in DI water) surrounding, 
and moving faster than, the jet was introduced, accelerating the jet to a desired 
smaller size below the nozzle opening. An acoustic excitation of controlled 
frequency and amplitude was launched into the jet using a piezoelectric transducer 
(Branson Ultrasonics) controlled by a frequency generator (Klewlett Packard model 
3325A). The jet was broken into a train o f uniform droplets, which were collected 
in a beaker containing a PVA solution and subsequently hardened for 2 ~ 5 h. The 
resulting microspheres were filtered, washed several times with DI water, and 
lyophilized.
3.2.3 Particle size distribution
A Coulter Multisizer 3 (Beckman Coulter, Inc.) equipped with a 200-pm
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aperture was used to determine the size distribution of the resulting EC MS. The 
EC MS were suspended in Isoton electrolyte with a dispersant to prevent 
aggregation. More than 5000 MS were counted for each sample.
3.2.4 Scanning electron microscopy (SEM)
The uniformity and surface morphology of the microspheres were 
examined using a Hitachi S-4700 scanning electron microscope. A droplet of an 
aqueous suspension of EC MS was placed on a small piece of silicon wafer 
attached onto a scanning electron microscope sample holder. The samples were 
dried overnight and sputter-coated with gold to facilitate SEM imaging. The MS 
were imaged at 2-10 kV.
3.2.5 Confocal Microscopy
A small amount of drug-loaded EC MS (~1 mg) was suspended in distilled 
water. A droplet of the resulting suspension was placed on a microscope slide and 
dried overnight. The drug-loaded MS were imaged using a laser scanning confocal 
microscope (Olympus Fluoview FV 300 Laser Scanning Biologic Microscope). 
Krypton and helium/neon lasers were used to excite rhodamine and piroxicam, 
respectively. The midsections of the MS were analyzed to determine the drug 
distribution at the center.
3.2.6 In vitro drug release
A known amount of EC MS loaded with piroxicam or rhodamine (~5 mg) 
was suspended in 1.5 ml of a PBS solution (pH = 7.4) containing 1% Tween 20. 
The suspensions were incubated at 37 °C for 24 h while continuously agitated by 
inversion (~8 rpm). At certain time intervals, the supernatant was sampled and 
the same volume refilled with a fresh buffer solution. Absorbance of the sampled
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supernatant was measured at 350 nm for piroxicam and 550 nm for rhodamine, 
respectively. The amount of drug release at each time interval was cumulatively 
added to the amount measured at the previous time interval and divided by the 
actual loading in the MS, resulting in cumulative percent release. The samples 
prepared with the same amount of blank MS were treated identically, and the 
absorbance values thus obtained were subtracted from all measurements.
3.3 Results
3.3.1 Preparation of drug-loaded microspheres
Uniform EC MS with drug loading were fabricated using the PPF method. 
The model drugs, piroxicam and rhodamine, were encapsulated as the 
representatives of water-insoluble and water-soluble drugs, respectively. For each 
viscosity of EC, three different sizes of MS were fabricated to study the effects of 
particle size and viscosity on drug release. Figure 3.1 shows the pictures of the 
resulting MS with two different viscosities (4 cp and 45 cp) taken by a scanning 
electron microscope (SEM), which provide clear visual evidence o f the uniformity 
of the MS. Piroxicam-loaded MS of 35-, 55-, and 85-pm diameters were fabricated 
using 4-cp EC and 30-, 55-, and 90-pm diameters using 45-cp EC (Table 3.1). 
Rhodamine-loaded MS were fabricated with 30-, 60-, and 105-pm diameter using 
4-cp EC and 20-, 60-, and 90-p.m diameter using 45-cp EC (Table 3.1). All MS 
exhibited much smaller sizes than the nozzle opening (250 pm) used for the 
fabrication in this study, which showed that the carrier stream functioned properly 
reducing the thickness of the EC solution jet. To further prove the uniformity and 
narrow size distribution of the EC MS, four different batches of the MS were 
measured using a Coulter Multisizer. As shown in Figure 3.2, uniform EC MS of 
various sizes were fabricated with more than 90% of the MS within ±3 pm of the
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average diameter.
3.3.2 Drug distribution in the microspheres
The drug distribution inside of the MS is one of the critical factors 
governing drug release. To examine the drug distribution, the mid-section of the 
drug-loaded MS was inspected using confocal fluorescent microscopy. The 
intensity of the emission light corresponded to the relative concentration of the 
drug. Grattard et al. [41] previously examined the distribution of fluorescein- 
labeled protein in spray-dried EC MS and observed uncontrolled distribution 
profiles possibly due to the polydispersity of the EC MS. The monodisperse EC 
MS fabricated in the present work exhibited drug distributions specific to each 
precisely controlled size.
Figure 3.3 shows piroxicam and rhodamine distributions inside the EC MS. 
It appears that rhodamine is more hydrophilic than piroxicam, which, in turn, is 
more hydrophilic than EC. As a result, only the small EC MS (30- and 35-pm) 
exhibited relatively homogeneous piroxicam distributions, where, due to the rapid 
particle hardening, the drug had little time to diffuse outwardly toward the aqueous 
media. Larger MS, therefore, showed higher piroxicam concentrations near the 
particle surface. For rhodamine, possibly due to its hydrophilicity, the high drug 
concentrations near the surface were more notable regardless of the MS size and 
EC viscosities. Still, due to rapid hardening, the 20- and 35-pm MS showed more 
evenly distributed rhodamine.
The above results are consistent with our previous observations with PLG 
MS, which showed that piroxicam in the PLG MS exhibited higher concentrations 
at the center while rhodamine localized at the surface, due to the different affinities 
of the drugs for the polymer and aqueous phase [52]. Piroxicam might be more 
hydrophobic than PLG, causing it to localize toward the center while rhodamine,
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being less hydrophobic (or more hydrophilic) than PLG, may have moved 
outwardly toward the aqueous media during hardening.
3.3.4 In vitro drug release study
Figure 3.4 shows the results from the in vitro drug release experiments, 
which elucidate the effects on the release kinetics of the particle size, viscosity of 
EC, and intraparticle drug distribution. The effects of MS size were dominant in 
piroxicam release, which could be explained by the relationship between the MS 
size and the surface-area-to-volume ratio (Figures 3.4(A) and (B)). The larger the 
MS, the smaller the surface-area-to-volume ratio, reducing the flux of piroxicam 
out o f the particles. For 4-cp EC, however, the release from the 55-pm MS at the 
beginning was faster than that from the 35-pm MS. The drug, highly concentrated 
near the surface as shown in Figure 3.3(B), seemed to cause faster release from the 
55-pm MS [66]. The initial burst of piroxicam from the 55-pm MS of 45-cp EC 
could also be explained by the high drug concentrations at the surface. For the 90- 
pm MS of 45-cp EC, the large size and high polymer viscosity appeared to 
suppress the release during the initial 8 h.
The effect o f polymer viscosity on rhodamine release was quite dramatic. 
As shown in Figures 3.4(C-D), the total percent release during the first 24 h for the 
45-cp MS was below 8% while that for the 4-cp MS was 20 -  60 %. For the 60-pm 
MS, the total release increased from 8 to 40% as the viscosity decreased from 45- 
to 4-cp. For 45-cp MS, 60-pm particles exhibited faster release (~ 8%) than the 
other sizes (< 2%). However, due to the overall slowdown in release, the size effect 
of the 45-cp MS was minimal. On the other hand, the release o f rhodamine from 4- 
cp MS exhibited a stronger dependence on MS size (Figure 3.5(C)). For instance, 
the total percent release during the first 24 h for 105-pm MS was 20% whereas it 
was 60 % for 30-pm MS.
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3.4 Discussion
The size, size distribution, and viscosity of the EC MS strongly influence 
the in vitro drug release profiles. Given a particular drug and carrier polymer, the 
surface area-to-volume ratio (i.e., the particle size) most critically influences the 
intraparticle drug distribution and the diffusive drug release, which, in turn, dictate 
the drug release kinetics. The PPF method provided us the means by which to 
fabricate piroxicam- and rhodamine-loaded uniform EC MS with precisely 
controlled sizes, as shown in Figures 3.1 and 3.2. This, in turn, enabled us to 
elucidate the parameters affecting the drug release without the uncertainties 
resulting from non-uniform particle size.
The effects of MS size and polymer viscosity on the drug release have 
been investigated by many researchers. For instance, the release o f isosorbide 
dinitrate or potassium chloride in EC MS was reported to increase as the MS size 
decreased [10, 63], Arabi et al. [67] showed that higher polymer viscosity retarded 
the allopurinol release more. However, these investigators could not accurately 
control the MS size by varying the surfactant concentration, agitation rate, or sieve 
size and had to settle with wide size distributions. As a result, accurate analysis of 
the effects of MS size and polymer viscosity was not possible. In the present work, 
the uncertainties originating from MS size variation were eliminated using uniform 
EC MS (Figures 3.1 and 3.2) fabricated by the PPF method and a release profile 
specific to each MS size was obtained.
The drug release profiles are influenced by the properties of the MS such 
as the particle size, polymer viscosity, and intraparticle drug distribution. For 
example, due to high EC viscosity, as shown in Figures 3.4(C) and (D), the total 
percent release of rhodamine during the first 24 h was minimal (< 8%) for all MS 
of 45-cp EC while more than 60% of release was obtained with the 30-pm MS of 
4-cp EC. The effects of MS size were also notable in drug release from the MS of
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4-cp EC (Figures 3.4(A) and (C)). That is, the larger the MS, the slower the drug 
diffusion out of the particles. . However, interestingly, the release from the 30- and 
35-pm MS was more sustained than that from the larger MS, 55- and 60-pm in 
diameters, respectively. The drug, highly concentrated near the surface as shown in 
Figure 3.4(B), seemed to be responsible for the fast drug release at the beginning 
from the 55- and 60-pm MS resulting in less sustained drug release than the smaller 
MS [66].
Reduction of initial burst and sustained release of the drug has been widely 
studied for hydrophilic drugs such as proteins and peptides since significant initial 
burst is not only dangerous to the body but also undesirable for a long-term release 
[68]. To realize zero-order release, which is considered the optimal release of 
nonsteroidal anti-inflammatory drugs such as ketoprofen, the reduction o f initial 
burst is necessary [69]. It was reported that the release of fenoterol HBr, a highly 
water-soluble drug, from EC MS exhibited a reduced initial burst with the addition 
of nonsolvent such as petroleum benzene during the microsphere hardening [65]. 
Yamada et al. [69] realized an approximate zero-order release of ketoprofen by 
coating the Eudargit particles with a mixture of carboxymethylethylcellulose and 
EC. However, the size distributions of their microspheres were not precisely 
controlled, thereby still leaving the unresolved issue o f reproducibility due to the 
polydispersity of MS.
The monodisperse EC MS of 30- and 35-pm size, fabricated with the PPF 
method reported herein, exhibited approximate linear release with reduced initial 
bursts. As mentioned above, the fast hardening of the small MS might give rise to 
more even drug distributions and prevent massive dissolution of the drug from the 
surface at the initial stage of the release of both hydrophobic and hydrophilic 
model-drugs. Most importantly, due to the precise control of the size and size 
distribution, the critical parameters governing the drug release, such as the surface-
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area-to-volume ratio and intraparticle drug distribution, could be controlled highly 
consistently and reproducibly for each specific size of the MS.
3.5 Conclusion
We have developed a novel method of fabricating drug-loaded uniform EC 
MS with precisely controlled sizes and size distributions. Both acoustic and 
hydrodynamic forces were used to produce the MS. The effects of the MS size and 
EC viscosity on the drug release kinetics were examined. The size effects were 
quite evident with the piroxicam release. The initial burst of piroxicam from the 55- 
pm MS may be explained by the high drug concentrations at the MS surface. The 
rhodamine release from 4-cp MS varied according to the MS size. The release from 
the 45-cp MS was slow due to the higher viscosity. The 30- and 35-pm MS of the 
lower viscosity showed approximate linear release with a reduced initial burst 
possibly due to the relatively uniform drug distributions. The EC MS prepared by 
the PPF method could realize sustained drug release with high reproducibility.
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3.6 Figures and Table
Figure 3.1 SEM pictures o f drug-loaded uniform EC MS with different sizes 
and EC- viscosities. The drugs loaded and EC viscosities are (A) piroxicam, 
4 cp; (B) piroxicam, 45 cp; (C) rhodamine, 4 cp; and (D) rhodamine, 45 cp. 
The diameters of the MS are, from top to bottom, (A) 35, 55, 80 pm; (B) 30, 
55, 90 pm; (C) 30, 60, 105 pm; and (D) 20, 60, 90 pm. The scale bars are 50 
pm.
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Figure 3.2 Size distributions of four different batches of EC MS 
fabricated with the PPF method.
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Figure 3.3 Confocal laser micrographs o f drug-loaded EC MS with 
different sizes and EC viscosities. The light intensity indicates piroxicam 
and rhodamine distributions. The scale bar is 30 pm. The drugs loaded 
are (A)-(C) piroxicam, (D)-(F) rhodamine, (G)-(I) piroxicam, and (J)-(L) 
rhodamine. The EC viscosities are (A)-(F) 4cp, and (G)-(L) 45 cp. The 
diameters are (A) 35 pm, (B) 55 pm, (C) 80 pm, (D) 30 pm, (E) 55 pm, 
(F) 90 pm, (G) 30 pm, (H) 60 pm, (I) 105 pm, (J) 20 pm, (K) 60 pm, and 
(L) 90 pm.
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Figure 3.4 Drug release profiles from EC MS with different sizes and EC 
viscosities. The drugs and EC viscosities are (A) piroxicam, 4 cp; (B) 
piroxicam, 45 cp; (C) rhodamine, 4 cp; and (D) rhodamine, 45 cp.
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Table 3.1 Average diameters EC microspheres fabricated by the present method
Polymer
Viscosity
Average
Diameter
(pm)
35(±1.5)
4 cp 55(±2.6)
80(±3.0)Piroxicam
30(±2.4)
45 cp 55(±3.0)
90(±2.5)
30(±1.5)
4 cp 60(±1.5)
Rhodamine B 105(±2.3)
20(±1.0)
45 cp 60(±2.0)
90(±2.5)
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CHAPTER 4
A NOVEL ELECTRIC FIELD ASSISTED METHOD FOR FABRICATION 
OF UNIFORM BIODEGRADABLE HYDROGEL MICROSPHERES
A modified PPF method enabling fabrication of uniform biodegradable 
hydrogel microspheres o f precisely controlled size has been developed. Especially, 
with the use of electric force, the method allows surfactant-free and nontoxic 
particle fabrication. Four different hydrogels, including chitosan, starch, and 
gelatins with two distinct polarities, were utilized as the model polymers.
4.1 Hydrogel Microspheres for Controlled Drug Release
Hydrogel MS were widely investigated as drug delivery vehicles due to 
their advantages including tissue compatibility and ease of swelling and, solute 
permeability [14]. The MS using hydrogel polymers such as chitosan and starch 
have been of particular interest for controlled drug release.
Chitosan is a natural cationic hydrogel and has been used as the 
encapsulation materials for biodegradable microspheres [15, 16]. The drugs such as 
prednisolone sodium phosphate, melatonin, and theophylline were encapsulated in 
CMS resulting in prolonged drug release [16, 70-73]. Due to the bioadhesiveness 
of chitosan, CMS were used for site specific delivery [19, 20, 35], Morphine, 
which has low bioavailability administered in simple solution, was loaded in CMS 
and exhibited rapid adsorption to the lung with high bioavailability [19], In 
eradicating Helicobacter pylori, which is etiologically linked to chronic gastritis, 
peptic ulcer disease, and gastric cancer, the CMS containing tetracycline increased 
the residence time in the stomach, thus resulting in high drug efficacy [20, 35].
CMS are also well known as a good protein and/or as DNA delivery 
vehicle because of their cationic charge [15, 17, 18]. Positively charged CMS can
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form a polyion complex with a negatively charged protein thus prolonging the 
release. The plasmid DNAs such as pGL2 and pMK3 showed sustained and high 
protein production using CMS as carrier [17]. The CMS containing transforming 
growth factor-pi (TGF-pl) were incorporated into the tissue scaffold augmenting 
the cell proliferation and production of extracellular matrix [15, 18].
Starch, another natural hydrogel, has been explored for its use as a drug 
delivery vehicle because it is inexpensive, inert, biocompatible, and biodegradable 
[21]. The MS of various starches were studied as adjuvant in oral immunization 
and protein delivery system [22, 23, 74-77]. Polyacryl starch MS were examined as 
a drug delivery system for vaccination and successfully induced mucosal and 
systemic immune responses using antigens such as rotavirus, human serum 
albumin, and diphtheria toxin [22, 23, 74, 77]. The proteins such as bovine serum 
albumin, horseradish peroxidase, and insulin, were encapsulated in poly(acryloyl- 
hydroxyethyl starch) MS and exhibited good stability and prolonged release [75, 
76],
Gelatin microspheres (GMS) have been of great interest in recent years 
because o f its excellent biocompatibility and degradation to non-toxic products 
[24], The administration routes such as nasal, gastrointestinal and rectal ways were 
suggested in conjunction with using GMS as drug carrier due to their good 
mucoadhesive properties [26, 78-80], Carboplatin, an antitumor drug was 
encapsulated in GMS and successfully delivered via the nasal route with very high 
lung-targeting efficiency [56] and calcitonin, which has a low bioavailibility when 
administered via the oral route, also resulted in enhanced nasal adsorption [81]. 
Interleukin-10 (IL-10), an anti-inflammatory cytokine, was delivered via rectal 
routes of female mice and inhibited colonic mucosal inflammation more efficiently 
when GMS were used as delivery vehicles [26],
In addition to bioadhesiveness, GMS are well known as good protein
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delivery vehicles since they can be positively or negatively charged and can form a 
polyion complex with an oppositely charged protein thus prolonging the protein 
release [27, 28]. Proteins complexed with gelatin hydrogel are known to be 
released through the degradation of gelatin. Due to these properties, GMS have 
been widely used as a delivery vehicle for growth factors in tissue engineering [25, 
30, 82-88]. Growth factors are known to contribute to tissue regeneration at 
different stages o f cell proliferation and differentiation [88, 89]. However, due to 
their short half-lives, an appropriate delivery vehicle is needed to maintain 
therapeutically efficacious levels of the growth factors in vivo. Basic fibroblast 
growth factor (bFGF) was impregnated in gelatin sponge or GMS with isoelectric 
point (IEP) of 5.0 (acidic gelatin) and exhibited prolonged vascularization, 
accelerated tissue regeneration and improved therapeutic efficacy o f cardiomyocyte 
transplantation [25, 82, 84, 85]. Adipose or periodontal tissue regeneration was also 
enhanced with bFGF-impregnated GMS [86, 87, 90], Other basic growth factors, 
such as transforming growth factor-pi (TGF-pi) and hepatocyte growth factor 
(HGF), were also encapsulated in acidic GMS and released in a controlled manner, 
demonstrating that it is a promising therapy for the articular cartilage defect and the 
liver cirrhosis [30, 83, 88]. For bone morphogenic protein (BMP), basic gelatin 
(IEP = 9.0) was used as the carrier to form polyionic complex and demonstrated 
enhanced alkaline phosphatase (ALP) activity [29].
4.2 Conventional Fabrication Methods and Their Problems
To fabricate hydrogel MS, various methods, such as aqueous precipitation 
[16, 20, 36], classic emulsion [24, 30], and spray drying [40, 91], were often 
employed. The hydrogel solution drops were formed by agitating, with high- 
pressure air, the suspension or the hydrogel solution resulting in random breakup of 
the droplets. Thus, the resulting MS exhibited wide size distributions, which caused
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possible uncertainties in drug release profiles. Various other approaches with better 
control have also been attempted by using a membrane with uniform pores [92], a 
microreactor [93, 94], and a spinning disk [95]. Although fairly uniform MS were 
obtained with these methods, the difficulties still remained because the drop size 
depended on the solution viscosity, the reactor shape, and the size of pore or disk- 
tooth. For example, to fabricate small MS of a viscous polymer, one might need a 
very high pressure to allow the solution to pass through the small pores o f the 
membrane and/or the micro-reactor. For the same reason, a spinning disk might 
require high rotating velocity to generate strong centrifugal force, which could be 
limited by the capacity of a motor. Occasionally, aqueous hydrogel solution caused 
the wetting on the membrane surface hindering the drop formation at each pore.
4.3 Fabrications and Characterization of Uniform Hydrogel Microspheres
The PPF scheme was suggested as a means to overcome the limitations 
described above. Although the basic PPF scheme worked well, for the following 
reasons the fabrication of hydrogel MS was challenging and required further 
improvement of the method. First, hydrogel materials were dissolved in water to 
make the working polymeric solutions, which were often highly viscous. To 
appropriately introduce the hydrodynamic force, therefore, an oil phase was chosen 
as a carrier stream, which exhibited viscosity comparable to that o f the hydrogel 
solution. Aqueous carrier stream would mix rapidly with hydrogel solution before 
it functioned properly [2, 52-54, 96]. Second, solvent removal from the hydrogel 
solution drops was more demanding than that from the oil-soluble polymer drops 
wherein the solvents were volatile. For instance, methylene chloride used for the 
PLG MS fabrication could be removed efficiently at room temperature without 
employing any extra process [2, 52-54]. Third, various attempts, including the use 
o f surfactants, failed to prevent the drops suspended in oil phase from coalescing
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[55, 56]. Thus, a new approach was required to separate the hydrogel drops and 
avoid their agglomeration. Finally, to be practically useful, the apparatus and the 
processing protocols must be suitable for scale-up production.
In this section, we report on first successful fabrication o f monodisperse 
MS of biodegradable hydrogels and an apparatus enabling it. The hydrogel 
polymers tested included chitosan, hetastarch, and gelatin. Gelatins with two 
different isoelectric points (IEPs = 5 and 9) were used because they are well known 
for delivery of oppositely charged proteins [27, 30],
4.3.1 Materials
Chitosan (75-85% deacetylated) was purchased from Aldrich. Hetastarch 
solution (6% hetastarch in 0.9% sodium chloride injection; Abbott laboratories), 
hetastarch was a gift from Professor Timothy M. Fan of the Department of 
Veterinary Clinical Medicine, and gelatins of two different IEPs (IEPs = 5.0 and 
9.0; Mw = 100 kDa; Nitta Gelatin Co., Osaka, Japan) were a gift from Professor 
Russell D. Jamison of the Department of Materials Science and Engineering. 
Professors Fan and Jamison are with the University of Illinois at Urbana- 
Champaign.
4.3.2 Preparation of uniform hydrogel microspheres
Herein, we report a novel method for fabricating monodisperse MS of 
biodegradable hydrogels. The hydrogel materials used in this work were chitosan, 
hetastarch, and gelatins with IEPs of 5 and 9, respectively. To generate uniform 
hydrogel solution drops, canola oil was chosen as a nontoxic and nonsolvent carrier 
stream material to effectively apply the hydrodynamic force [2, 52-54]. As the 
hydrogel solution was fed through the nozzle, it formed a smooth jet of a size 
smaller than the nozzle opening, which subsequently was broken up into uniform
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droplets by the acoustic excitation as described in Chapter 2 [50, 51]. Figure 4.1 
shows the thus-produced uniform hydrogel drops of 200-, 150-, 100-, and 50-pm in 
diameter using a nozzle with 250-pm opening. All drops exhibited smaller sizes 
than the nozzle orifice.
Once generated, the hydrogel drops were collected in an oil bath and 
subjected to hardening. Unfortunately, to minimize the surface tension energy, 
liquid drops are inclined to recombine and form larger drops unless prevented. 
However, even with the use of surfactants it has been extremely difficult to prevent 
the drops suspended in oil phase from coalescing [55, 56]. In this work, we 
introduced an electric field to charge the drops so that they could repel each other 
and maintain their integrity (Figure 2.2). Due to the coulombic repulsion, the 
charged hydrogel solution drops were prevented from agglomeration during the 
hardening process resulting in uniform dry MS. The fact that this process involved 
no toxic surfactants qualified the method to be particularly attractive for biomedical 
applications such as advanced drug delivery and tissue engineering. Figure 4.2 
shows the effect of charging on the hydrogel solution drops 150-p.m in diameter. As 
the electric field was applied, the drops were repelled due to the coulombic force. 
With more charging, the separation of the drops increased.
While separated in oil, the drops were subjected to hardening to give dried 
hydrogel MS. The oil, utilized as the hardening media, helped the MS to attain 
smooth surface morphology due to its high surface tension force. In general, air- 
dried microparticles exhibit nonspherical and rough morphologies due to the low 
interfacial tension between the air and the hydrogel solution [39, 40, 97]. For the 
chitosan and hetastarch MS, water used as the solvent was boiled off by elevating 
the temperature of the oil bath. This evaporation method, however, was 
inapplicable to gelatin because of its degradation at high temperatures. Therefore, 
gelatin solution drops were gelled by lowing the temperature o f the oil bath to 0 ~
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4 °C, followed by extraction of water using acetone to obtain dried MS [27], The 
gel-drops were rigid enough not to agglomerate even after charge disappeared.
4.3.3 Characterization
The MS were examined using a Hitachi S-4700 scanning electron 
microscope (SEM). A droplet of MS samples suspended in hexane was placed on a 
small piece of silicon wafer attached on top of the SEM sample holder and dried 
overnight with desiccant. The samples were sputter-coated with gold. The MS were 
imaged at 2-10 eV.
4.4 Results and Discussions
Figure 4.3 shows thus-fabricated MS of chitosan, hetastarch, and gelatin. 
Regardless of the materials used, all MS exhibited excellent uniformity and 
sphericity. The average diameters of the CMS (Figure 4.3(Al-3)) were 15 pm, 20 
pm and 28 pm; hetastarch MS (Figure 4.3(Bl-3)) were 17 pm, 30 pm, and 45 pm; 
GMS of IEP = 5 (Figure 4.3(Cl-3)) were 25 pm, 40 pm, and 50 pm; and GMS of 
IEP = 9 (Figure 4.3(Dl-3)) were 20 pm, 30 pm, and 40 pm. The size uniformity 
was further verified with a Coulter Multisizer. Figure 4.4 illustrates the precisely 
controlled size and narrow size distributions for the four different batches of the 
CMS. More than 90% of the MS were fabricated within ±3 pm of the average 
diameter.
To verify that the MS of chitosan and hetastarch were properly formed as 
solid particles through solvent evaporation, their cross-sections were examined. As 
shown in Figure 4.5, the insides of the MS were densely packed regardless of the 
MS sizes, which proved that for both hydrogel polymers, the use o f a high- 
temperature oil bath removed the solvent appropriately. The porosity of the MS 
was known to be a critical factor in determining the drug release profile [7, 98, 99].
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The smooth and dense structures of both CMS and HMS could allow one to tailor 
the drug release with better control.
The GMS, when suspended in water at body temperature, dissolve rapidly, 
thus are not suitable as vehicles for sustained drug delivery. Therefore, crosslinking 
was often carried out to prepare nondissolving GMS (0.125% glutaraldehyde). 
Figure 4.6 shows the dry GMS after crosslinking, which were no longer spherical 
but exhibited rough surfaces (Figures 4.6). Although the IEP = 9.0 GMS exhibited 
smoother surfaces than those of IEP = 5, the dimples were still shown. However, 
the crosslinked GMS after water uptake retained their uniformity and sphericity as 
shown in Figure 4.7, which was meaningful from the perspective of controlled drug 
release because the actual drug release occurred in aqueous environment. The most 
important advantages of the PPF drop generation method described in this work 
would be the flexibility in controlling the drop size and the capability to perform 
large-scale production. The use of carrier stream enabled the PPF to overcome the 
limitations imposed by solution viscosity and nozzle dimension. Therefore, drops 
of different sizes could be generated with a fixed nozzle simply by varying the flow 
rate of the carrier stream and/or the frequency o f acoustic excitation. With a single 
set o f nozzle, the achievable size range was quite wide. By increasing the number 
of nozzles subjected to acoustic excitation, the amount of hydrogel MS produced 
would increase by the same number. Therefore, scale-up could be easily established 
with the present method. Also, the production rate would not change with the 
changing target drop size because, at a fixed flow rate, uniform drops of wide size- 
range could be obtained by varying the frequency of acoustic excitation.
4.5 Conclusion
We have developed a novel method particularly suited to fabricating 
uniform hydrogel MS of precisely controlled size and size distribution. Chitosan,
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hetastarch, and gelatins (IEPs = 5.0 and 9.0) were used as the model hydrogel 
materials. Use of carrier stream in combination with acoustic excitation facilitated 
the fabrication of uniform solution drops so that the solution viscosity and nozzle 
size would no longer limit the uniform MS fabrication of controlled size. By 
applying electric charge, the hydrogel solution drops could be prevented from 
coalescing during the hardening process, requiring no surfactant. In addition, with 
the present method, scaling-up could be easily realized by increasing the number of 
nozzles. Excellent uniformity and smooth spherical shape were exhibited for the 
hydrogel MS fabricated herein, both dry and swollen containing drug solution, 
which may provide accurate control in the drug delivery mediated by hydrogel 
particles. This study demonstrated that the fabrication o f MS could be extended to a 
wide range of hydrogel materials with excellent control in size.
4.6 Figures
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Figure 4.1 Generation of uniform hydrogel solution drops. Four different 
sizes of uniform drops generated by the present method. Drop diameters 
are (A) 200 pm, (B) 150 pm, (C) 100 pm, and (D) 50 pm.
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Figure 4.2 Charging was used to prevent chitosan drop agglomeration via 
coulombic repulsion. The applied electric fields were (A) 0 V/cm, (B) 50 
V/cm, (C) 100 V/cm, and (D) 150 V/cm. The drop diameters are 150 pm.
Figure 4.3 SEM pictures of uniform hydrogel microspheres. The polymers 
used are (A) chitosan, (B) hetastarch, (C) IEP = 5 gelatin, and (D) IEP = 9 
gelatin. The diameters are (A l) 15 pm, (A2) 20 pm, (A3) 28 pm, (B l) 17 pm, 
(B2) 30 pm, (B3) 45 pm, (C l) 25 pm, (C2) 40 pm, (C3) 50 pm, (DI) 20 pm, 
(D2) 30 pm, and (D3) 40 pm. The scale bars are (A) 15 pm and (B-D) 30 pm.
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Figure 4.4 Size distributions o f hydrogel MS (chitosan) prepared by 
PPF method. Four different batches were measured by Coulter 
Multisizer and exhibited narrow size distributions.
Figure 4.5 SEM pictures o f the cross sections of the MS. The polymers used 
were (A)-(C) chitosan and (D)-(F) hetastarch. The diameters are (A) 15 pm, 
(B) 20 pm, (C) 28 pm, (D) 17 pm, (E) 30 pm, and (F) 45 pm. The scale bars 
are (A)-(C) 5 pm and (D)-(F) 10 pm.
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Figure 4.6 SEM pictures of dry GMS after crosslinking. The GMS at dry 
state were shown. The gelatins are IEP = 5.0 from (A) to (C) and IEP = 9.0 
from (D) to (F). The scale bar = 30 pm.
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Figure 4.7 Optical micrographs of uniform GMS after crosslinking. The 
GMS after water-uptake were shown. The gelatins are IEP = 5.0 from (A) to 
(C) and IEP = 9.0 from (D) to (F). The diameters after swollen are (A) 55 
pm, (B) 90 pm, (C) 120 pm, (D) 45 pm, (E) 70 pm, and (F) 80 pm. The scale 
bar =100 pm.
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CHAPTER 5
DRUG RELEASE PROFILES OF UNIFORM GELATIN MICROSPHERES 
UNDER DIFFERENT CROSS-LINKING CONDITIONS
GMS were often crosslinked using glutaraldehyde to form nondissolving 
MS for sustained drug delivery. Due to the diffusion of glutaraldehyde, the 
crosslinking density in the MS could be heterogeneous, influencing their drug 
release kinetics. In this study, uniform GMS were fabricated with the PPF method 
and the effects of crosslinking elucidated without possible uncertainties caused by 
the particle polydispersity.
5.1 Crosslinked Gelatin Microspheres
Cross-linking density is one of the critical parameters affecting the 
degradation of GMS [100, 101], which would consequently determine the drug- 
release profile. Glutaraldehyde has been used as one of the most effective cross- 
linking agents. However, due to its cytotoxicity [102, 103], it is desirable to 
minimize the use of glutaraldehyde in the cross-linking of gelatin. Although less 
toxic agents, such as genipin and D,L-glyceraldehyde, have been used, they were 
not as efficient as glutaraldehyde [24, 104], For practical application of GMS as a 
delivery vehicle, it is important to understand the drug-release profile as a function 
of cross-linking, which, in turn, would allow tailoring of the release profile.
Conventionally, GMS are fabricated by the emulsion method and cross- 
linked in an aqueous solution of glutaraldehyde [27], The cross-linking reaction 
takes place as glutaraldehyde diffuses through the GMS, which may give rise to a 
concentration gradient of glutaraldehyde along the path and lead to heterogeneity 
of the cross-linking density in the GMS. This could be a significant factor affecting 
the drug release profile of GMS. However, to study such phenomenon,
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monodisperse GMS are required so that any uncertainties resulting from size 
nonuniformity of the spheres could be eliminated. For instance, the diffusion of 
glutaraldehyde and drug and the decomposition o f GMS would depend on 
microsphere size. Unfortunately, due to the difficulty in controlling the GMS size, 
such well-defined GMS have not been available to date. As a result, the study on 
drug-release profile o f GMS as a function of cross-linking has been hampered.
In this work, we fabricated uniform-sized GMS of IEP = 9 as described in 
Chapter 4 using glutaraldehyde as the cross-linking agent [105] and studied the 
effect of cross-linking on the drug distribution inside the GMS and the drug-release 
profile. The concentrations of glutaraldehyde used for the cross-linking reaction 
were 0.125 -  0.875 % as summarized in Table 5.1. The in vitro drug-release study 
was performed utilizing trypan blue, an acidic model drug, to effect the formation 
of charge complex. The critical parameters governing the drug release, such as the 
drug distribution in the microspheres and the in situ degradation profile of the MS, 
were examined.
5.2 Experimental
5.2.1 Cross-linking uniform gelatin microspheres
Uniform GMS, 60 pm in diameter, were fabricated as described in Chapter 
4. The resulting GMS were cross-linked using galutaraldehyde. The un-cross- 
linked GMS were first suspended in cold water (0 ~ 4°C) o f different 
glutaraldehyde concentrations (Table 5.1) and cured for 24 h. The resulting GMS 
were filtered, washed with DI water, and agitated in glycine solution to block 
excessive aldehyde groups. After 2 h, the GMS were washed again with DI water 
and lyophilized.
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5.2.2 Drug loading
An acidic model drug (trypan blue) was impregnated into IEP = 9 GMS to 
form polyion complex. Briefly, an aqueous solution containing the drug (0.1% w/v) 
was dropped onto the known amount of GMS (5 pL/mg) and left for 2 h at room 
temperature. The drug solution was completely absorbed by the GMS because the 
volume of the solution was less than that required for the theoretical equilibrium 
swelling o f the GMS.
5.2.3 In vitro drug release study
The in-vitro drug release study was preformed utilzing two distinct release 
media of PBS with and without an enzyme (Collagenase 1A) [30], The enzyme 
concentration used in this work (373 ng/mL) mimicked the synovial fluid of a 
patient with osteoarthritis disease. Drug-loaded GMS were suspended in 1.5 mL of 
the release media and incubated at 37 °C for 18 days with continuous agitation. The 
supernatant was sampled at scheduled time intervals. Optical absorption of the 
sampled supernatant was measured spectrophotometrically.
5.2.4 Observation of intraparticle drug distribution
To examine the drug distribution in the MS, the GMS were loaded with 
acid fluorescent dye (Aexa Fluor 430), and the intensity of the emitted light at the 
cross-sections was observed using the confocal fluorescent microscope (Olympus 
Fluoview FV 300 Laser Scanning Biological Microscope). The initial drug 
distribution was obtained of the GMS 2 h after the drug loading. To examine 
ionically complexed drug distribution, the drug-loaded GMS were suspended in 
phosphate buffered saline (PBS) without enzyme for 15 days to remove the 
nonbonded drug.
44
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
5.2.5 Zeta-potential measurement
Zeta potential is a measure of the charge that develops at the interface 
between a solid surface and its liquid medium. Thus, by measuring the zeta- 
potential of homogeneously cross-linked gelatin particles, the change in the charge 
of gelatin molecules due to cross-linking density could be identified. The gelatin 
solution (5% w/v) was cross-linked under different glutaraldehyde concentrations 
(Table 5.1) at 50 °C for 5 h. The resulting solutions were rapidly cooled down at -  
50 °C and lyophilized. The cross-linked gelatin was ground into small particles and 
suspended in PBS (pH = 7.4) after filtration (5-pm pore). The zeta-potential of the 
suspension was measured five times using Malvern Zetasizer 3000.
5.2.6 In situ degradation study
In situ degradation profiles o f the GMS were examined to study the effect 
o f crosslinking conditions. Differently cross-linked GMS were placed in the 
enzyme-containing PBS solution. At scheduled intervals, the GMS were drawn and 
observed under an optical microscope.
5.3 Results and Discussion
Figure 5.1 shows the SEM and optical microscope images of the GMS 
before and after cross-linking. The GMS before cross-linking exhibited excellent 
uniformity and smooth surface with an average diameter of 60 pm. However, 
regardless of the glutaraldehyde concentrations used, the dry GMS after cross- 
linking exhibited “crumpled” shapes although the size appeared to be alike. 
Because the drug release occurred in an aqueous environment, the integrity of the 
GMS upon water uptake was more important. Thus, the dry crosslinked-GMS were 
suspended in a phosphate buffered saline solution (PBS, pH = 7.4) for one day and 
observed using an optical microscope. As shown in Figure 5.1(C), the wet GMS
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restored the spherical shape and uniformity regardless o f the cross-linking 
conditions, which proved that the control on the size and morphology were still 
viable with the crosslinked GMS. The average diameter of the swollen GMS was 
restored to 100 pm regardless of the cross-linking conditions.
Figure 5.2 shows the in vitro drug release profiles of the drug-loaded GMS 
with and without the enzyme (i.e., collagenase 1A) in the release-media [30, 83], 
The concentration of the enzyme used herein was 373 ng/mL to mimic the synovial 
fluid of the patient with osteoarthritis disease. Without the enzyme, about 40% of 
the drug was released in 3 days, and no significant amounts afterwards. All the 
samples exhibited similar release-profiles regardless of the glutaraldehyde 
concentrations used for the cross-linking. This was not unexpected since the drug 
bound to the gelatin matrix would not be released without the decomposition of the 
gelatin and consequently the drug-release would be a diffusion-controlled process.
In the presence of enzyme, the total release was increased to 100% for all 
the samples (Figure 5.2(B)) due to the degradation of gelatin. The samples, Cl and 
C2, exhibited a 100% total release in 9 and 10 days, respectively, and C3 in 15-18 
days, indicating that the release was retarded as the glutaraldehyde concentration 
increased. Interestingly, no further retardation was observed for the samples C4 and 
C5 in spite of their higher glutaraldehyde concentrations. With the C6 sample, the 
total release seemed to be retarded further, but its release profile was similar to 
those of the samples C3, C4, and C5. This was intriguing since the cross-linked 
gelatin was reported to become more resistant to degradation with higher 
glutaraldehyde concentrations, resulting in prolonged release [29, 100], To 
elucidate the release profile of the cross-linked GMS, it is crucial to understand the 
drug-distribution in the GMS as a function of the glutaraldehyde concentration 
since the heterogeneous cross-linking density in the GMS described previously 
might have caused a nonuniform drug-distribution in the sphere, affecting the
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release profile.
An acidic fluorescent dye, Alexa fluor 430, was used as a model drug to 
study the drug distribution within the GMS using a confocal fluorescent 
microscope. The intraparticle drug distribution was measured before and after 
suspending the drug-loaded GMS in a PBS solution (pH = 7.4) for 15 days to 
ensure the release of the drug that was not bound to the gelatin. No enzyme was 
used to eliminate the effects resulting from the enzymatic degradation of the gelatin. 
Figure 5.3 shows the drug distribution in the GMS after 2 h and 15 days, which 
represent the initial drug distribution and the distribution of the drug complexed to 
the gelatin, respectively.
The initial drug distribution curve of the sample C l, which was concave- 
downward, indicated that the drug was populated more at the center. As the 
glutaraldehyde concentration increased, the amount of the drug near the surface 
increased and the shape of the intraparticle drug distribution curve changed to 
concave-upward for the sample C3. This could be attributed to the facile diffusion 
of the drug during its loading into the GMS center at the lower degrees of cross- 
linking. Interestingly, no significant change was observed for the samples C4 -  C6 
although the glutaraldehyde concentration increased further. On the other hand, the 
relative amount of the drug complexed to the gelatin matrix near the surface 
decreased as the glutaraldehyde concentration increased for the samples Cl -  C6. 
This could be explained by the inhomogeneous cross-linking, i.e., higher cross- 
linking at the GMS surface and lower toward the surface, caused by the 
concentration gradient of the glutaraldehyde along the diffusion path of the GMS.
The basicity of the gelatin would be weakened as its s-amino groups 
reacted with glutaraldehyde during the cross-linking process [106, 107]. 
Consequently, the driving force for the complexation of the acidic drug with the 
basic gelatin would be reduced with higher cross-linking. The effect of the cross-
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linking density on the charge of the basic gelatin was investigated by measuring the 
zeta-potential of the bulk gelatin as a function of cross-linking. To induce 
homogeneous cross-linking, gelatin was cross-linked in an aqueous solution using 
the glutaraldehyde concentrations in Table 5.1 followed by the removal of water. 
Figure 5.4 shows the zeta-potentials of the cross-linked bulk gelatin as a function 
of the glutaraldehyde concentration. The label corresponded to the glutaraldehyde 
concentration used for cross-linking (Table 5.1). The results indicated that the zeta- 
potential o f the gelatin decreased significantly as the cross-linking density 
increased. As a result, the samples with the glutaraldehyde concentration higher 
than 0.325% exhibited negative zeta-potential. This supports the intraparticle drug 
distribution in Figure 5.3. The increase in the glutaraldehyde concentration would 
be more effective near the GMS surface. Therefore, at higher glutaraldehyde 
concentrations, the lowering of the zeta-potential would be more prevalent near the 
surface than the center, reducing the complexation of the drug to gelatin even if the 
initial drug distribution was higher near the surface.
To study the effect o f cross-linking on the GMS degradation, the 
morphology o f the GMS during the enzymatic degradation process was monitored 
using the optical microscopy. It is well known that the gelatin with higher cross- 
linking would be more resistant to the enzymatic degradation. Figure 5.5 shows the 
optical micrographs of the degradation profiles of the GMS cross-linked with 
different amounts of glutaraldehyde. At day 6, the samples C l and C2 eroded into 
fragments while C3-C6 maintained their integrity with some deformation. C3 lost 
its integrity at day 9 and C4-C6 at day 12. It was rather intriguing to observe a 
similar decomposition pattern for the samples C4—C6 regardless of the 
glutaraldehyde concentration used for the cross-linking. While the bulk behavior of 
the samples C4-C6 were similar, the optical images at day 6 revealed interesting 
details of their decomposition pattern: C3 and C4 exhibited cracked surface and C5
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and C6 elongated opening on the surface with significant reduction in size. For 
comparison, the GMS suspended in a PBS solution without enzyme retained their 
integrity without any visual evidence of degradation.
Since the amount of drug complexed to the gelatin would be higher at the 
center and lower at the surface, the decomposition and release of the gelatin from 
inside the sphere would play a critical role in the drug release process of the GMS. 
This may explain the similar drug release profiles for samples C3-C6 regardless of 
the different glutaraldehyde concentrations used for the cross-linking. To explain 
such effect, the net release of the ionically complexed drug was examined. Figure 
5.6 shows the plot of the amount of drug release without enzyme (i.e., the 
diffusional release) subtracted from that with enzyme. Because the drug release by 
diffusion was removed, such plot would represent the release of ionically 
complexed drug solely incorporated with the GMS degradation.
For the first 2 days, the release profiles did not show much difference 
regardless of glutaraldehyde concentrations, which corresponded to the results 
shown in Figure 5.5. The GMS at day 2 did not exhibit discernible difference in 
erosion regardless of glutaraldehyde concentrations. However, at days 3-6, the 
difference became noticeable. Especially at day 6, the differences in the release 
were maximal because of the distinctive decomposition patterns o f the GMS. As 
shown in Figure 5.5, Cl and C2 eroded into fragments while C4-6 still retained the 
integrity of the surface. However, because the center of the GMS eroded into 
fragments, continuous drug release was seen until day 9. Although C4-6 swelled 
back to the original size and spherical shape, the drug release was minimal possibly 
due to the small amount of complexed drug near the surface of the GMS.
One of the factors causing the different decomposition patterns of these 
samples would be the concentration gradient of glutaraldehyde in the microsphere. 
For the samples with high glutaraldehyde concentrations, the increase in
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glutaraldehyde concentration would lead to more cross-linking at the surface, 
which would retard the diffusion o f glutaraldehyde into the center even further. 
Figure 5.5 supports the lower cross-linking density at the center. As a result, the 
decomposition would take place at the center while the surface remained intact, 
resulting in pressure build-up inside the sphere to develop cracks or openings 
depending on the cross-linking density at the GMS surface. The shrinkage of the 
GMS could be due to the release of the decomposed gelatin-matrix through these 
cracks or openings.
The intraparticle drug distribution patterns in Figure 5.3 may provide 
further insight on the decomposition pathways, wherein the curve for the initial 
drug distribution was changed from concave-downward to concave-upward as the 
sample switched from C2 to C3. This, in conjunction with the decrease in the 
amount of complexed drug at the surface, indicated a drastic increase in the cross- 
linking density at the surface, leading to the retarded decomposition o f the GMS 
surface. Therefore, one may envision the decomposition pattern of a GMS based on 
its intraparticle drug distribution and estimate the glutaraldehyde concentration 
needed for a desired drug release profile.
5.4 Conclusion
We investigated the drug release profiles of the GMS cross-linked with 
different glutaraldehyde concentrations. It was found that the effect of the 
glutaraldehyde concentration on the drug release profile was not linear, which was 
significant at its low end but negligible at its high end. The intraparticle drug 
distribution patterns indicated that the population of the complexed drug near the 
GMS surface decreased as the glutaraldehyde concentration increased. The zeta- 
potential measurements revealed that the low drug-gelatin complexation near the 
GMS surface reflected its high cross-linking density. The degree o f cross-linking at
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the surface seemed to be an important factor determining the decomposition pattern 
of the GMS, affecting the drug release profile. At higher glutaraldehyde 
concentrations, the GMS surface would be more cross-linked, leading to more 
resistant to degradation and less drug complexation. Under this situation, the drug- 
release profile would be mostly governed by the decomposition and release of the 
inner mass via the cracks or openings on the surface. Therefore, above the 
threshold value wherein the GMS would follow such decomposition pattern, the 
effect of glutaraldehyde concentration on the drug release profile would be 
negligible. The threshold glutaraldehyde concentration would vary as the GMS size 
varies, however, one may estimate it based on the intraparticle drug distribution 
patterns, which reveal the cross-linking profiles o f the GMS. This study 
elucidated the factors affecting the drug release profile and demonstrated that the 
tailoring of the drug release profile could be realized using the uniform sized GMS.
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5.5 Figures and Table
B
Figure 5.1. SEM and optical micrographs of uniform GMS prepared by the 
PPF method: (A) dry GMS before cross-linking, (B) dry GMS after cross- 
linking, and (C) wet GMS after cross-linking. The scale bars are 50 pm.
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Figure 5.2 In vitro drug release from uniform GMS with different cross- 
linking conditions. The release media used are pH = 7.4 PBS solutions 
(A) with enzyme and (B) without enzyme.
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Figure 5.3 Drug distribution profiles inside o f the GMS. The GMS were loaded with acid fluorescent dye 
(Alexa Fluor 430), and the light intensity at the cross-sections was observed using the confocal fluorescent 
microscope. The top row corresponded with the initial drug distributions and the bottom row the ionically 
complexed drug distributions.
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Figure 5.4 Zeta potentials of differently crosslinked gelatin. The label 
corresponds to the GA concentration used for crosslinking
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Figure 5.5 In situ degradation study with uniform GMS prepared under 
different crosslinking conditions. The PBS with enzyme was utilized as the 
suspension media. Each column represents a specific crosslinking condition 
employed for the GMS and each row the time of observation. For 
comparison, the GMS suspended in the media without enzyme were shown 
on the right-most column. The scale bars are 50 pm.
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Figure 5.6 Net release profiles of ionically complexed drug. The values 
of the diffusional release subtracted from those of enzymatic release were 
plotted.
Table 5.1 Different glutaraldehyde concentrations utilized to cross-link the uniform 
GMS
Sample
Name
Cl C2 C3 C4 C5 C6
Glutar­
aldehyde 
Cone. (%)
0.125 0.250 0.325 0.500 0.625 0.875
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CHAPTER 6
UNIFORM CHITOSAN MICROSPHERES WITH DIFFERENT
CROSSLINKING DENSITIES FOR ORAL DRUG DELIVERY
Uniform CMS with different cross-linking densities were fabricated to 
investigate their suitability as oral delivery vehicles. Drugs with three different 
polarities (base, weak acid, and strong acid) were utilized to examine the effect of 
polyion complex. The drug release profiles were investigated by using media with 
continuously changing pHs to mimic the gastrointestinal fluids.
6.1 Chitosan Microspheres for Oral Drug Delivery
CMS have been widely used as drug-delivery vehicles due to their 
biocompatibility, biodegradability, and bioadhesiveness [108-113]. Especially, the 
CMS with bioadhesiveness were known to increase the residence time at the 
mucosal surfaces in the stomach or intestine, improving the drug adsorption. For 
this reason, various therapeutic agents, such as Vitamin C, theophylline, aspirin, 
and griseofulvin, were encapsulated in the CMS for oral administration, resulting in 
sustained release [109, 114, 115]. The CMS were also investigated for oral immune 
delivery. The antigen encapsulated in CMS was protected from degradation and 
was gradually released enhancing the immune response [108, 116-118].
In addition, the CMS were favored due to their cationic property. An 
anionic drug complexed with CMS was shown to prolong the release. Especially 
for proteins and peptides, the interactions with CMS were reported to improve 
loading capacity, drug stability, and bioactivity [119, 120], Due to such ionic effect, 
the CMS often exhibited pH-dependent release [114, 121], which could be applied 
to various drugs for colon-specific delivery. For viral gene delivery, DNA needed to 
be protected through the gastrointestinal tract until it was delivered to a specific
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colonic site [109], The drug known to have an adverse effect on the stomach 
needed to suppress its release at low pH but be continuously released from the 
small intestine [122], Such control was governed by both ionic interaction between 
chitosan and the drug, and the pH of the release media. Unfortunately, the CMS 
passing through the gastric media often exhibited considerable amount of drug 
release due to their higher swelling and/or dissolution at low pH [109, 123],
6.2 Purpose
Various attempts were made to control the pH-dependent drug release from 
CMS. One approach was to incorporate anionic polymer such as alginate. The MS 
were fabricated with a combined use o f both chitosan and alginate, whose bonding 
strength varied due to the pH [124, 125], Thus, the drug release was determined by 
the mass ratio of the two polymers. Coating the CMS with various polymers, such 
as cellulose acetate butyrate, ethyl cellulose, and Eudragits, was also suggested to 
suppress the burst of drug release in gastric fluid [118, 122, 126, 127]. Because of 
the additional polymer barrier formed on the CMS, the drug by-passed the stomach 
but was released afterwards.
Although such methods could provide better control, there were several 
disadvantages. Firstly, additive polymers could change the cationic property of 
chitosan, thus degenerating the bioadhesiveness, and/or the polymer-drug 
interaction. The weaker polymer-drug interaction might lower drug stability and 
loading capacity. Secondly, the method often required an unfavorable process. To 
coat the CMS with hydrophobic polymers, an organic solvent was needed [118, 
122, 126, 127], which would not be suitable for encapsulation o f proteins, peptides, 
and DNA due to their degradation. Most of all, the size of the MS was not precisely 
controlled resulting in possible uncertainties and poor reproducibility in drug 
release.
59
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
As noted before, drug release from MS-based delivery systems critically 
depends on the size and size distribution of the MS because the surface area-to- 
volume ratio strongly influences the rate of out-diffusion o f the drug and/or 
degradation of the polymer matrix. The MS size was also known to be a critical 
determinant in site-specific delivery. The MS less than 10 pm were reported to be 
effective for the particle transportation via Peyer’s patches [31]. However, the 
methods often employed for fabrication of CMS, such as aqueous precipitation [16, 
35], classic emulsion [124, 128] and spray drying [40, 129], did not produce 
uniform MS due to lack of control over atomization. Membrane with uniform pores 
was utilized to control the size o f chitosan solution drops [113, 130]. Although the 
resulting CMS exhibited a fairly uniform size, the method still depended on pore 
dimension and solution viscosity, which did not provide enough flexibility in size 
control.
In this study, we have fabricated monodisperse CMS for oral delivery 
vehicles as previously reported [105]. Due to the excellent uniformity and narrow 
size distribution, the drug release from the resulting CMS could be accurately 
tailored. In addition, the present method did not involve any organic solvent or 
toxic surfactant, which would be favorable for biomedical applications aimed in 
this work. As stated above, the CMS were known to cause burst release at lower pH 
due to their swelling and dissolution. Thus, the crosslinking agent, glutaraldehyde 
was employed to fabricate acid-resistant CMS [130, 131]. To minimize the adverse 
effect of glutaraldehyde [103], all CMS used in this study were weakly crosslinked 
(Table 6.1). Due to the cationic nature of chitosan, therapeutic agents, such as 
anionic proteins and DNA, could be well encapsulated in and protected by CMS 
while passing through the GI tract. To examine such electric interaction and its 
effect on drug release, model drugs with three different polarities were employed, 
which were toluidine blue (TO; basic), trypan blue (TR; strong acid), and
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diclofenac sodium salt (DS; weak acid). TR represented the drug containing 
multiple anionic functional groups, such as protein. DS is known to cause the 
adverse effect on the gastric cavity but well adsorbed in the colon [132, 133], 
which would be advantageous if  released less at the stomach but continuously near 
the colon.
6.3 Materials and Methods
6.3.1 Materials
Chitosan (75-85% deacetylated) was purchased from Aldrich, and the 
model drugs (TR, TD, and DS) and glutaraldehyde (25% in aqueous solution) from 
Sigma. Glacial acetic acid and acetone with high purity were obtained from Fisher 
Scientific.
6.3.2 Preparation of uniform chitosan microspheres
Uniform CMS were prepared following the method described in Chapter 4. 
Briefly, to fabricate uniform CMS, the chitosan solution (1% w/v) was prepared in 
0.2 M acetic acid solution, which was subsequently crosslinked using 
glutaraldehyde (Table 6.1). A smooth liquid jet of this solution, much thinner than 
the nozzle opening was generated with the use of carrier stream and subsequently 
broken up into uniform droplets using acoustic excitation. To prevent the 
agglomeration, the drops were electrically charged so that coulombic repulsion 
kept them separated. The uniform chitosan-solution drops were suspended in a hot 
oil bath (150 ~ 160 °C) to boil off water. The resulting CMS were collected by 
filtration, washed with acetone to remove the residual oil, and lyophilized.
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6.3.3 Drug loading in chitosan microspheres
The model drugs with different polarities were impregnated in CMS. 
Briefly, the PBS solution (pH = 7.4) containing the drug (TR, 5% w/v; TD, 5%; SD, 
0.5%) was dropped onto the known amount of CMS (1 (il/mg) and cured for 3 h at 
room temperature. The solution volume was less than the theoretical equilibrium 
swelling volume of the CMS resulting in complete absorption.
6.3.4 Characterization
The uniformity and morphology of the dry CMS were observed using a 
Hitachi S-4700 scanning electron microscope. A droplet of CMS suspended in 
hexane was placed on a small piece of silicon wafer attached on top of a scanning 
electron microscope sample holder and dried overnight with desiccant. The 
samples were sputter-coated with gold. The GMS were imaged at 2-10 eV. The 
swollen CMS were observed using an optical microscope. To prepare the 
completely swollen MS, a small amount of CMS (~ 1 mg) was suspended in 1 mL 
of two distinct buffer solutions at pHs = 7.4 and 1.0 and left for 24 h at room 
temperature. To observe the size change due to swelling, more than 50 MS were 
measured for three different cases: dry, wet at pHs = 7.4 and 1.0.
6.3.5 Drug distribution in the microspheres
The midsections of the MS were analyzed to determine the drug distribution 
at the center. To examine the effect of the drug polarity, two different fluorescent 
dyes were employed. Rhodamine B and Eosin Y represented the basic and acidic 
drug, respectively. The drug-loaded CMS were imaged using a laser scanning 
confocal microscope (Olympus Fluoview FV 300 Laser Scanning Biologic 
Microscope).
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6.3.6 In vitro drug release
Drug-loaded CMS were placed in 1.5 mL of the release media, whose pHs 
were gradually increased to mimic the fluid through the gastrointestinal tract. The 
pHs were maintained at 1 for 1 h, 2 for 1 h, 5 for 2 h, 6.8 for 4 h, and 7.4 for 4 h. 
The release media contained the dispersant (0.5% v/v Tween 80) to prevent CMS 
agglomeration. The suspensions of drug-loaded GMS were incubated at 37 °C 
while continuously agitated by inversion (~8 rpm). Absorbance of the sampled 
supernatant was measured spectrophotometrically. The amount of drug release at 
each time interval was summed from the amount measured at the previous time 
interval resulting in cumulative release.
6.4 Results
6.4.1 Differently crosslinked uniform chitosan microspheres
Uniform CMS with different crosslinking densities were fabricated as 
previously described in this dissertation [105], The chitosan was cross-linked 
utilizing glutaraldehyde of different concentrations (Table 6.1) and for each 
crosslinking density, the CMS with three different sizes were made (Table 6.2). 
Figure 6.1 shows the resulting CMS. The average diameters were 24 pm, 28 pm, 
and 35 pm for CO; 23 pm, 29 pm, and 38 pm for C l; and 25 pm, 28 pm, and 38 pm 
for C2. Regardless of the crosslinking density, all MS exhibited excellent 
uniformity (std < 1.33 pm). The rough surface of the MS was known to cause 
initial burst due to the increase in the surface area [40], Thus, it is important to 
obtain the smooth surface morphology. Our method proved to be beneficial 
because it provided the CMS with smooth surfaces regardless o f their size and 
crosslinking density as shown in Figure 6.2.
The CMS after water uptake were examined, from which the drug was
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actually released. Figures 6.3 and 6.4 show the CMS swollen at two different buffer 
solutions of pHs = 7.4 and 1.0, respectively. Due to the water uptake, the diameters 
of the CMS increased during suspension in the aqueous media. Even after the swell, 
the CMS retained excellent uniformity (std < ±1.70) and sphericity, which provided 
further proof that the particle size control, was accurately maintained throughout 
the present drug release study. Figure 6.5 and Table 6.2 show the sizes of the CMS 
in two different states: dry and wet in two different buffer solutions (pHs = 7.4 and 
1.0). Regardless of crosslinking density, the diameter of the CMS increased more at 
pH = 1.0 than at 7.4. Due to the weak crosslinking, the hydrolysis of chitosan 
seemed to be more incorporated at the lower pH resulting in more swelling. 
Therefore, the size differences between each batch of the CMS became as large as 
18 pm while the dry CMS showed 10 pm at most (Table 6.2).
6.4.2 Drug distribution
The drug distribution in the CMS is one of the most critical factors in drug 
release. To examine the effect o f drug-chitosan ionic interaction, fluorescent dyes 
with two distinct polarities were employed as the model drugs, which were 
Rhodamine B (basic) and Eosin Y (acidic). The cross sections of the drug loaded 
CMS were observed using a confocal fluorescent microscope. Figures 6.6 and 6.7 
show the basic and acidic drug distributions in the CMS, respectively. The basic 
drug was homogenously distributed throughout the CMS while the acidic drug was 
more concentrated near the surface regardless of the size and cross-linking density 
of the CMS. In this study, to encapsulate the drug, the drug solution was absorbed 
into the dry CMS. Thus, the drug loading was determined by two competing factors, 
the diffusion of the drug solution into CMS and the ionic interaction between the 
drug and chitosan. The basic drug, which has the same polarity with chitosan, 
seemed to be freely mobile resulting in homogenous distribution mainly caused by
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in-diffusion of the drug solution. However, for the acidic drug, due to the attractive 
force between the drug and chitosan, the drug molecule appeared to complex with 
chitosan at the same time when the drug solution diffused into the CMS. The drug 
complexed at the CMS surface seemed to be unable to diffuse into the center 
resulting in high drug concentration near the surface of the CMS.
6.4.3 In vitro drug release study
An in vitro drug release study was carried out to examine the effect of the 
ionic interaction by employing model drugs with three different polarities (TO, TR, 
and DS). The pHs of the release media were gradually increased to simulate the 
fluids throughout the gastrointestinal tract. Figure 6.8 shows the release profiles of 
the basic drug (TO). Regardless of the size and cross-linking density, the release 
was not sustained possibly due to the electrostatic repulsion between the CMS and 
the drug. Almost 100% release was obtained in 10 min with all CMS.
However, for the strong acidic drug (TR), the effect of the CMS size and 
cross-linking density was clearly visible (Figure 6.9). For non-cross-linked CMS 
(CO), all the release profiles merged into one, possibly due to their high dissolution 
in the release media. However, as the cross-linking density increased, the size 
effect became notable (Figures 6.9(B) and (C)). Interestingly, the release was more 
sustained as the size decreased. Although the small CMS were supposed to exhibit 
faster release due to their large surface area-to-volume ratio, it seemed that for 
strong acidic drug, the ionic interaction played a more important role than drug out- 
diffusion. In this study, the drug was loaded into CMS by absorption o f the drug 
solution prepared at pH = 7.4. The resulting CMS, when suspended in pH = 1 .0  
media, would be more protonated, resulting in stronger cationic charge. Such 
change in ionic property seemed to depend on the size of the CMS. Namely, the 
smaller CMS experienced faster protonation in the media of low pH possibly due to
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their large surface area, resulting in more drug complex. Because the acidic drug 
was more concentrated near the surface as shown in Figure 6.7, such dependency 
on the surface area would be more dominant with strong acid drug. Thus, as shown 
in Figures 6.9(A) and (B), as the size decreased (i.e., more susceptibility to pH), the 
drug was released less. The drug release after 1 h was minimal for all small 
crosslinked CMS (<10%). The effect of cross-linking density, although weak, was 
also noticeable. As the crosslinking density increased, the total percent release 
decreased more, possibly due to the stronger resistance to acid. The total percent 
release during the first 12 h with large CMS decreased from 45.1% to 34.5%, with 
medium CMS from 36.4% to 12.5%, and with small CMS from 10.0% to 7.1%.
For the weak acid drug (DS), the release was more sustained than the basic 
drug and more continuous than the strong acid drug (Figure 6.10). Due to the 
weaker ionic bonding, the release seemed to depend more on the diffusional release, 
which could also explain the minimal influence of the crosslinking density. 
Therefore, although the small CMS might have been protonated more rapidly at 
low pH, the release was still the fastest due to the drug out-diffusion facilitated by 
their large surface area-to-volume ratio. The release profiles exhibited biphasic 
patterns, which consisted of the initial burst and the subsequent continuous release. 
Importantly, the larger the CMS, the less the burst, possibly due to the small 
surface area-to-volume ratio. The small CMS exhibited more than 70% release 
during the first 1 hr while the large CMS showed less than 50% release. After the 
burst release, the release was almost linear for all CMS (~1.25%/hr). Regardless of 
the crosslinking density, the small CMS could obtain the total 100% release during 
12 h.
To further prove complete release of the basic drug and the remainder of the 
strong acidic drug, the color of CMS after 24 h drug release was examined using an 
optical microscope. Figure 6.11 shows that the CMS initially loaded with basic
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drug became transparent proving that there was no drug remaining. However, as 
shown in Figure 6.12, the dark bluish color of strong acidic drug (TR) indicated 
that there was the drug complexed in the CMS even after 24 h release.
6.5 Discussion
The CMS were widely investigated as oral delivery vehicles due to 
excellent biocompatibility, bioadhesiveness and especially cationic property, that is, 
pH-dependent release. Drugs such as antigen, DNA, protein, and/or some anti­
inflammatory agents, would be more efficacious if  delivered specifically to the 
colonic site [109, 113, 125]. However, the chitosan alone as the encapsulant was 
known to be undesirable due to its massive hydrolysis at low pH resulting in burst 
release near the stomach [123]. Several attempts incorporating other polymers as 
additives were made to improve the drug release behavior, which, however, could 
be unfavorable due to possible deterioration o f the cationic property of CMS and 
incorporation of undesirable solvent into CMS [118, 122,125, 127, 128].
In this study, we suggest, and investigate, uniform CMS of precise size and 
size distribution as a promising colon-specific delivery vehicle. The CMS were 
crosslinked to make them tolerant to acidic fluid so that they could bybass the 
gastric cavity [131]. However, low glutaraldehyde concentrations were utilized to 
minimize the adverse effect. Instead of introducing other additives, precise control 
over the size and size distribution of the CMS enabled the drug release to be 
tailored accurately. Even after 24 h suspension in the media of both pHs = 7.4 and 
1.0, the uniformity and sphericity of our CMS were well retained (Figures 6.3 and 
6.4). One of the appealing scenarios of colon targeting was that the drug in the 
carrier could be retained as much as possible in the upper gastrointestinal tract but 
released near the colon by the degradation o f the encapsulant polymer [133, 134]. 
Therefore, in this study, we examined the remaining drug after 12 h as the potential
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drug for colon-specific delivery because the pH near the colon would be constant at
7.4 hence no more effect of the pH changes on drug release.
Drugs of three different polarities were employed and their release profiles 
investigated to assess the feasibility of using our uniform CMS for colon specific 
delivery. For the delivery of basic drug (TO), the CMS were shown to be 
unfavorable. Due to the strong repulsion between the drug and chitosan, the free 
drug molecules appeared to be released instantaneously regardless o f the size and 
crosslinking density of the CMS (Figure 6.8). However, for strong acid drug, more 
than 90% of the drug could be retained with the small CMS of weak crosslinking 
density (Cl and C2) even after 12 h suspension in the release media (Figure 6.9). 
The model drug utilized in this study, TR, had multiple anionic functional groups 
(-SO3), which might be able to represent strong anionic proteins, peptides, and 
DNA. Colon-specific delivery of such therapeutic agents were known to be 
beneficial for their systematic absorption [109, 113, 134, 135], However, 
polydisperse CMS might lower the efficiency because, as shown in Figure 6.9, 
larger CMS lost almost half the drug in 1 h. In this sense, small CMS (23-25 pm) 
with C l and C2 were attractive for colon-specific delivery. Precise control over the 
size and size distribution of CMS allowed for maximization o f the amount of drug 
that could potentially be released at the colon, through degradation o f chitosan.
The release of the weak acid drug exhibited the biphasic profiles: an initial 
burst and the subsequent continuous release (Figure 6.11). The model drug, DS, 
was known to cause local side effects if released too much in the stomach, 
prompting the need for colon-specific delivery [122, 123, 125, 133]. All CMS in 
this work exhibited a burst, which could be lowered by increasing the CMS size. 
As shown in Figure 6.10, large CMS (35 -38 pm), regardless of the crosslinking 
density, exhibited less than 50% bursts. Thus, while the small CMS exhibited 100% 
release in 12 h, more than 40% of the drug still remained in the large CMS, which
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was again the potential amount o f the drug that could be released by CMS 
degradation [133, 134]. Unlike with the strong acid drug, the large CMS would be 
favorable for colon-specific delivery of the weak acid drug.
Additional coating on the CMS was suggested as a means to completely 
prevent the DS release at the stomach [118, 122, 127]. However, although almost 
no DS was released at the gastric fluid, the size of CMS was not properly 
controlled thus exhibiting fast release or lack o f control after the coating materials 
disappeared. Use of our uniform CMS as the core would be the promising design 
for colon-specific delivery of DS. The polymers with pH-dependent solubility, such 
as Eudragits, could protect our uniform CMS at the gastric cavity, which would 
subsequently be exposed to both higher pH and colonic enzyme and release the 
drug in a controlled manner due to their precise size and size distribution.
6.6 Conclusion
Uniform CMS with different crosslinking densities were fabricated for use 
as oral delivery vehicles. To study their efficacy for colon-specific delivery, model 
drugs with three different polarities, which were base, strong acid, and weak acid, 
were employed and encapsulated in the CMS. The drug distributions in the CMS 
showed that the basic drug was homogeneously distributed while the acid drug was 
more concentrated near the surface, which proved the charge interaction between 
the drug and chitosan. The basic drug appeared to be not a good candidate for 
colon-specific delivery because o f its fast release. However, for strong acid drugs 
such as anionic proteins or peptides, the small CMS with weak crosslinking could 
be more favorable due to the increased amounts of the drug complexed with the 
CMS, which would be released by degradation of the CMS at the colon. Weak acid 
drug, possibly due to the weak bonding strength, showed continuous release during 
the first 24 h. However, to minimize the burst at the gastric cavity, use of large
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CMS was suggested. The uniform CMS in this study were judged to be promising 
oral delivery vehicles of anionic drugs due to the accurately controlled release 
profiles facilitated by their monodispersity.
6.7 Figures and Tables
Figure 6.1 SEM micrographs of uniform CMS with different crosslinking 
densities. CMS with three different sizes were fabricated for each 
crosslinking condition. The crosslinking conditions utilized were (A 1-3) CO, 
(Bl-3) C l, and (Cl-3) C2. The diameters were (A l) 24 pm, (A2) 28 pm, 
(A3) 35 pm, (B l) 23 pm, (B2) 29 pm, (B3) 38 pm, (C l) 25 pm, (C2) 28 pm, 
and (C3) 38 pm. The scale bars = 20 pm.
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Figure 6.2 Surface morphology of uniform CMS. Regardless of their size 
and cross-linking density, smooth surfaces were observed. The cross-linking 
conditions utilized were (Al-3) CO, (Bl-3) C l, and (Cl-3) C2. The diameters 
were (A l) 24 pm, (A2) 28 pm, (A3) 35 pm, (B l) 23 pm, (B2) 29 pm, (B3) 
38 pm, (C l) 25 pm, (C2) 28 pm, and (C3) 38 pm. The scale bars = 5 pm.
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Figure 6.3 Optical micrographs of the wet CMS swollen in pH = 7.4 buffer 
solution. The cross-linking conditions utilized were (Al-3) CO, (Bl-3) C l, and 
(C l-3) C2. The diameters were shown in Table 6.2. The scale bars = 50 pm.
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Figure 6.4 Optical micrographs of the wet CMS swollen in pH = 1 . 0  buffer 
solution. All CMS swelled more than in pH = 7.4. The cross-linking conditions 
utilized were (Al-3) CO, (Bl-3) C l, and (Cl-3) C2. The diameters were shown 
in Table 6.2. The scale bars = 50 pm.
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Figure 6.5 The sizes of uniform CMS with different crosslinking densities. 
The dry CMS were suspended in the media at pHs = 7.4 and 1.0 for 24 h. 
More than 50 CMS were measured optically.
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Figure 6.6 Distribution of a basic drug in the CMS as observed by confocal 
fluorescent microscope. Rhodamine B was employed as the model drug. The 
crosslinking conditions were (Al-3) CO, (Bl-3) Cl, and (Cl-3) C2. The scale 
bars were 20 pm.
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Figure 6.7 Distribution of an acidic drug in the CMS as observed by 
confocal fluorescent microscope. Eosin Y was employed as the model drug. 
The cross-linking conditions were (Al-3) CO, (Bl-3) Cl, and (Cl-3) C2. The 
scale bars were 20 pm.
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Figure 6.8 Release profiles of a basic drug (toluidine blue) from uniform 
CMS with different cross-linking densities. The cross-linking densities 
were: (A) CO, (B) C l, and (C) C2.
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Figure 6.8 Continued
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Figure 6.9 Release profiles of a strong acidic drug (trypan blue) from 
uniform CMS with different cross-linking densities. The cross-linking 
densities were (A) CO, (B) Cl, and (C) C2.
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Figure 6.10 Release profiles of a weak acidic drug (diclofenac sodium salt) 
from uniform CMS with different cross-linking densities. The cross-linking 
densities were (A) CO, (B) Cl, and (C) C2.
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Figure 6.11 Optical micrographs of the CMS after 12 h release of a basic 
drug (toluidine blue). All exhibited brownish color and transparency, which 
means a 100% release. The cross-linking conditions utilized were (A) CO, 
(B) Cl, and (C) C2. The scale bars are 50 pm.
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Figure 6.12 Optical micrographs of the CMS after 12 h release of a strong 
acidic dye (trypan blue). All exhibited dark bluish color indicating that there 
was drug remaining in the CMS. The cross-linking conditions utilized were 
(A) CO, (B) C l, and (C) C2. The scale bars are 50 pm.
Table 6.1 The concentrations of glutaraldehyde utilized to cross-link the CMS
Sample name CO C l C2
GA cone. (%) 0 0.0375 0.075
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Table 6.2 Average diameters of chitosan microspheres while dry and wet at both 
pHs = 7.4 and 1.0. More than 50 CMS were measured using an optical microscope
CO chitosan microspheres
Suspension media Small Medium Large
Dry air 24 (±0.43) 28 (±0.49) 35 (±1.33)
pH = 7.4 34 (±0.87) 36 (±0.87) 49 (±0.95)
pH = 1.0 37 (±0.27) 39 (±0.37) 54 (±0.92)
C l chitosan microspheres
Suspension media Small Medium Large
Dry air 23 (±0.51) 29 (±0.46) 38 (±1.07)
pH = 7.4 30 (±0.56) 36 (±0.87) 47 (±1.70)
pH = 1.0 33 (±1.15) 38 (±1.16) 56 (±1.39)
C2 chitosan microspheres
Suspension media Small Medium Large
Dry air 25 (±0.69) 28 (±0.27) 38 (±0.58)
pH = 7.4 31 (±0.73) 37 (±1.28) 47 (±1.11)
pH = 1.0 36 (±0.97) 41 (±1.24) 50 (±1.62)
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CHAPTER 7 
CONCLUSIONS
Drug delivery mediated by biodegradable and/or biocompatible 
microspheres (MS) have been of great interest because of their versatility, ease of 
preparation, and simplicity of administration through various routes. However, the 
conventional methods were only able to produce MS with wide size distributions, 
giving rise to uncertainties in the data interpretation and poor reproducibility of the 
results. Due to the surface-area to volume ratio, the size and size distribution of the 
MS are critical factors in determining the drug diffusion and/or polymer 
degradation, which in turn, influence the drug release. In this thesis work, we have 
developed novel, yet very effective and practical, methods of fabricating uniform 
MS of various biocompatible/biodegradable polymers. These MS were 
subsequently used to study the in-vitro drug release, in an effort to assess their 
utility as advanced drug delivery vehicles.
The basic scheme of the present fabrication method, namely the PPF 
method, originated from the work of my thesis advisor, Professor Kyekyoon 
(Kevin) Kim, which included fabrication of precision microspheres of frozen 
hydrogen and microcapsules of silica aerogel. Previously, the PPF method was 
applied to PLG and polyanhydride in our group and the resulting MS were used for 
the release study. Due to their excellent uniformity and narrow size distribution the 
MS exhibited precisely controlled drug release behaviors. In this work we have 
applied the scheme to different polymers such as ethyl cellulose (EC), chitosan, 
starch, and gelatin, to examine the effectiveness of the PPF method with other 
biomaterials.
The PPF method, extensively utilized and further developed in this study 
for fabrication of uniform MS, employed three different forces: mechanical,
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hydrodynamic, and electric. A combined use of the mechanical and hydrodynamic 
forces enabled the method to be free from usual limitations imposed by the solution 
viscosity and nozzle dimension. A nonsolvent carrier stream flowing faster than the 
polymer solution jet allowed the jet thickness to become smaller than the nozzle 
orifice, while the mechanical force caused break-up of the jet into uniform drops. 
Because EC dissolves in hydrophobic solvent, water was employed for the carrier 
stream. However, hydrogels such as chitosan, starch, and gelatin required the use of 
oil phase as a carrier stream, instead. Upon generation, the uniform drops needed to 
be separated to avoid agglomeration and retain their uniformity. The drop 
agglomeration was successfully prevented by employing a surfactant for EC and an 
electric force for hydrogels. Especially with the use of electric force, the method 
became truly non-toxic and most suitable for biomedical applications. The 
separated drops were subjected to hardening to obtain the dry MS. Depending on 
the kinds of solvent, their evaporation was facilitated either at room temperature or 
at an elevated temperature. Since gelatin degrades at high temperature, it required 
use of a low temperature to form gelled drops, followed by solvent extraction 
afterwards.
Conventional methods, often promoted by others for their effectiveness, 
could not achieve precise control over the MS size due to the restrictions imposed 
by the polymer kinds and reactor dimensions. However, the methods developed in 
this work overcame such limitations due to dynamic applications of various 
techniques employed that are possible with the PPF method. The concurrent use of 
three different techniques, which were the generation of uniform solution drops, 
prevention of agglomeration, and facilitation o f particle hardening, allowed us to 
achieve much more and with more control than any other available methods.
The strategy for selecting a polymer as an encapsulant was determined by 
the administration routes, kinds of drugs, and desirable release profiles. For
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example, EC was a good candidate for oral, buccal, and rectal delivery. Hydrogels 
could very well be appropriate delivery vehicles for hydrophilic therapeutic agents 
such as protein, peptide, and DNA. Thus, the ability to use a variety o f polymers 
proved to be the advantage and versatility of the MS-mediated drug delivery 
systems. In this study, we employed uniform MS of EC, chitosan, and gelatin as 
such delivery vehicles.
For EC, almost linear release could be obtained with small MS (30- and 35- 
pm) of low-viscosity EC. The precise control over the size enabled us to obtain 
more even drug distribution in the MS, by which the initial burst release could be 
substantially suppressed. We also examined the effect of crosslinking on uniform 
gelatin microspheres (GMS). Because GMS dissolved rapidly in aqueous solution, 
cross-linking was often carried out by suspending the non-crosslinked GMS in 
glutaraldehyde solution. Due to glutaraldehyde concentration gradient, 
heterogeneous crosslinking took place in the GMS, which provided the MS surface 
with stronger resistance to degradation but with less drug bonding. As a result, the 
release was not sustained longer with increased crosslinking although the GA 
concentrations increased from a certain value. We found that the size control of 
GMS was essential to optimization of crosslinking conditions, by which the 
cytotoxicity of glutaraldehyde could be minimized but the efficacy of drug delivery 
maximized. The chitosan microspheres (CMS) were also examined for colon- 
specific delivery. Various investigators had previously employed additive polymers 
to achieve colon-specific delivery. However, due to the complexity o f the 
fabrication method and the resulting incorporation of toxic solvent, the approaches 
did not appear to be desirable. In this work, because of the uniformity of the MS 
and the cationic property of chitosan, we were able to demonstrate that the release 
of an acidic drug could be accurately targeted to colonic site without any other 
additives.
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In conclusion, we have developed a novel method particularly suited to 
fabricating uniform biomaterial-based MS o f precisely controlled size and size 
distribution. We have demonstrated that the resulting MS were advantageous in 
achieving precisely controlled drug delivery. Due to its compatibility with a wide 
range of biomedical materials and applications, the present method should also be 
applicable to cell encapsulation, bio-imaging, fabrication of biological sensors, and 
even food engineering. With the proven flexibility and versatility of the PPF 
method and a number of applications demonstrated in this work, it is hopefully 
concluded that the present work may have planted a seed, if in a modest way, for 
the advancement and evolution of biomedical science and technology.
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